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ABSTRACT 
Hypertension is the most prevalent disease condition in the US affecting every 1 
in 3 American adults. Renin angiotensin system (RAS) predominately regulates 
blood pressure and fluid homeostasis in the body. Angiotensin II type 1 (AT1) 
receptor is the key component of RAS that is implicated in hypertension. 
Oxidative stress is considered one of the main causes of hypertension. Studies 
including in our own lab showed that oxidative stress increases renal AT1 
receptor function and contributes to hypertension. However, the exact 
mechanism of oxidative stress mediated increase in blood pressure is not 
completely known. Recent studies suggested that redox-sensitive transcription 
factors Sp3 and/or NF-κB regulate basal gene expression of AT1 receptor.  
Therefore, we designed studies to investigate the role of Sp3 and NF-κB in 
oxidative stress mediated hypertension or high blood pressure. We also 
designed studies to investigate the specificity of reactive oxygen species 
(superoxide vs. hydrogen peroxide) in regulating AT1 receptor function and high 
blood pressure.  
Results from cell culture studies (HK2 cells) demonstrated that SOD-
inhibitor DETC but not hydrogen peroxide significantly increased fluorescence 
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levels of superoxide probe dihydroethidium (DHE). Similarly, H2O2, but not 
DETC, treatment increased the fluorescence of the H2O2-sensitive probe 
dichloro-dihydro-fluorescein (DCFH). In addition, DETC, but not H2O2, increased 
the nuclear accumulation of Sp3 and NF-κB proteins. This effect was attenuated 
with tempol treatment. Furthermore, DETC increased AT1 receptor mRNA and 
protein expressions, which were attenuated with tempol treatment. However, 
H2O2 did not have any significant effect on AT1 mRNA expression. Results from 
transfection studies suggest that Sp3 plasmid increased while  
Sp3 siRNA decreased AT1 receptor protein expression. However, NF-κB plasmid 
failed to increase AT1 receptor protein expression. Immunofluorescence and 
biotinylation studies demonstrated that DETC treatment increased cell surface 
AT1 receptor. Moreover, angiotensin II increased PKC activity in vehicle-treated 
cells that further increased in DETC-treated cells, which was attenuated by AT1R 
blocker candesartan and SOD-mimetic tempol. 
Results from animal studies (SD rats) suggest that DETC treatment 
increased systolic and diastolic blood pressure, which were attenuated with 
tempol treatment. Furthermore, DETC treatment increased superoxide levels in 
kidney superficial cortex, which was attenuated with SOD-mimetic tempol. 
Candesartan infusion in DETC treated rats produced increased diuresis and 
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natriuresis compared to controls. Tempol in DETC treated rats attenuated 
candesartan-induced increased diuresis and natriuresis. Importantly, lysine 
acetylation of Sp3 protein, an index of Sp3 activation, was significantly higher in 
DETC treated rats, which was attenuated with tempol treatment.   
Our data in both in vivo rat experiments and in vitro cell culture studies 
suggest that superoxide via Sp3 transcription factor up-regulates renal AT1 
receptor function suggesting its role in hypertension. Specific targeting of 
superoxide and/or Sp3 may provide a selective and better therapeutic target to 
combat oxidative stress and/or its mediated effects responsible for hypertension 
and associated cardiovascular diseases. 
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1. INTRODUCTION AND STATEMENT OF PROBLEM 
Renin angiotensin system (RAS) is a hormonal cascade that regulates blood 
pressure and fluid homeostasis in the body (Crowley et al., 2006). In recent past, 
it is one of the most studied systems in the fields of hypertension, 
atherosclerosis, and cardiovascular and associated diseases. Also, this system is 
linked to cognitive disorders including Alzheimer disease and dementia (Allum, 
Hallissey, Ward, & Hockey, 1989). Ang II is an octapeptide that produces most of 
its physiological and pathophysiological functions by activating AT1 and AT2 
receptors, the two key G protein coupled receptors of RAS family (de Gasparo, 
Catt, Inagami, Wright, & Unger, 2000). However, most of the cellular and 
physiological functions of Ang II are mediated via AT1 receptor. Recent elegant 
studies by Crowley and Coffman, Navar, and others confirmed an independent 
RAS system in the kidney that helps regulate fluid homeostasis and blood 
pressure in the body (Coffman & Crowley, 2008; Navar, 2005). Hyper-activation 
of AT1 receptor in the kidney is linked to hypertension, cardiovascular and 
associated diseases (Crowley et al., 2006; Kobori, Nangaku, Navar, & 
Nishiyama, 2007). Despite extensive research, the exact mechanism of hyper-
activation of renal AT1 receptor contributing to hypertension is not known. 
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             During physiological conditions, normal levels of reactive oxygen species 
(ROS), as signaling molecules, play an important role in cellular and organ tissue 
functions including the kidney functions. ROS affect other signaling molecules by 
modulating intracellular redox state and oxidative modification of cellular proteins 
(Paravicini & Touyz, 2006). During pathophysiology, imbalances in redox state 
have been implicated in various diseases including hypertension, diabetes and 
other cardiovascular disorders. Recent studies in our lab showed that high level 
of oxidative stress up-regulate AT1 receptor function and high blood pressure in 
aging rat model (Chugh, Lokhandwala, & Asghar, 2011, 2012). However, 
molecular mechanism of oxidative stress associated renal AT1 receptor up-
regulation and hypertension is not well known.   
             There are various types of ROS in biological system such as superoxide, 
hydrogen peroxide (H2O2), hydroxyl radicals (OH•) and peroxynitrite (ONOO⁻) 
that are linked to oxidative stress associated hypertension and related 
cardiovascular disorders (Lassegue & Griendling, 2004; Paravicini & Touyz, 
2006). Studies in other labs including ours have shown that scavenging ROS 
with antioxidants lowers blood pressure in hypertensive animal models (Chugh et 
al., 2011, 2012; Wilcox, 2010). These studies establish a direct link between 
oxidative stress and hypertension in animal models. Moreover, a number of 
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studies have demonstrated that superoxide and H2O2 are the main ROS, which 
are responsible for hypertension and related diseases (Landmesser et al., 2002; 
Vaziri, Dicus, Ho, Boroujerdi-Rad, & Sindhu, 2003; Vaziri, Lin, Farmand, & 
Sindhu, 2003). In contrast, some other studies suggested that H2O2 is a 
vasodilator and helps reduce high blood pressure (Y. Chen, Pearlman, Luo, & 
Wilcox, 2007; Park et al., 2015; Schroder et al., 2012). Therefore, determining 
the specific role of superoxide and H2O2 in blood pressure regulation is 
warranted.   
             Specificity protein (Sp) including Sp3 belongs to redox-sensitive 
transcription factors family that regulates the expression of a myriad of genes 
involved in cell growth and differentiation, cell signaling, and inflammation (Lee et 
al., 2006; Nair et al., 2014; Vaziri, Lin, et al., 2003). Sp3 protein binds GC rich 
content of the promoter of these genes. Computer analysis and electrophoretic 
mobility shift assay (EMSA) suggest that promoter of AT1 receptor gene 
possesses two distinct GC rich content sites that are the putative binding sites for 
Sp3 transcription factor (Kambe, Kinjyo, Hiruki, & Kubo, 2004). Similarly, NF-κB 
is a redox-sensitive transcription factor that has been shown to regulate a myriad 
of genes involved in cell survival, differentiation and proliferation (Hayden & 
Ghosh, 2008). In addition, recent studies in our lab showed that oxidative stress 
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induced activation of NF-κB transcription factor plays an important role in 
regulating blood pressure (Banday, Fazili, & Lokhandwala, 2007; Bhatt, 
Lokhandwala, & Banday, 2014; L. George, Lokhandwala, & Asghar, 2009; L. E. 
George, Lokhandwala, & Asghar, 2012). Also, a number of studies have shown 
that activation of NF-κB modulates AT1 receptor expression (Cowling et al., 
2005). Preliminary computer analysis revealed two putative binding sites at-265 
and-2540 at AT1 receptor promoter for NF-κB transcription factor (Z. J. Chen, 
Parent, & Maniatis, 1996). However, a link between oxidative stress, Sp3/NF-κB 
and renal AT1 receptor is missing and warrants further investigations.  
Therefore, we designed in vivo and in vitro studies to investigate i) the 
role of redox-sensitive transcription factor Sp3 and NF-κB in the regulation 
of renal AT1 receptor expression and function, and ii) Specificity of ROS, 
i.e. superoxide vs. H2O2 and their role in the up-regulation of renal AT1 
receptor function and blood pressure.  
These studies were designed in human renal proximal tubule HK2 cell line and 
Sprague Dawley (SD) rats. 
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2. REVIEW OF LITERATURE  
2.1. Prevalence of hypertension  
Hypertension is one of the most common and perhaps the most complex chronic 
diseases, affecting more than 1 billion people across the globe (Lawes, Vander 
Hoorn, Rodgers, & International Society of, 2008). It is the most prevalent 
disease in the US affecting every 1 in 3 American adults. The present cost for the 
treatment of hypertension is about $46.4 billion in America and there is projection 
that shows it could rise to 274 billion by 2030 (Go et al., 2014). Moreover, 
hypertension is a clinical factor and is a major risk factor for cardiovascular 
diseases, heart attack, cognitive decline and dementia (Birns & Kalra, 2009), this 
will further increase the economic burden on the US health care system. 
Therefore, understanding the mechanism of hypertension is needed to better 
treat and prevent hypertension and associated diseases. 
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Figure 1. Prevalence of high blood pressure in adults ≥20 years of age by 
age and sex. 
(National Health and Nutrition Examination. Survey: 2007–2010). Source: 
National Center for Health Statistics and National Heart, Lung, and Blood 
Institute. 
2.2. Role of kidney in blood pressure regulation and fluid 
homeostasis 
Regulation of blood pressure and fluid homeostasis are vital physiological 
processes for human body to function properly. Regulation of blood pressure is a 
complex process that requires the integration of several organ system including 
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central nervous system (CNS), cardiovascular system, kidney, immune system, 
and adrenal glands. These systems together determine blood pressure levels by 
modulating cardiac out, fluid volumes, peripheral vascular resistance, and other 
various extrinsic disturbances. Notably, seminal studies from the groups like 
Guyton, Coleman and Coffman, and Navar showed that kidney is the 
predominant organ in the regulation of blood pressure and fluid homeostasis 
(Coffman & Crowley, 2008; Guyton, 1991; Navar, 2005). The arterial pressure 
rarely deviates 10 to 15 % from normal in an adult human each day.  Such 
constancy in blood pressure is achieved at three different levels and is corrected 
by three different systems present in our body: (i) Neuronal receptors react within 
minutes to correct any abnormal blood pressure, (ii) hormonal system follows the 
neuronal system within minutes, and (iii) within hours or days, kidney pressure 
control system comes in and correct the abnormal blood pressure (Coffman & 
Crowley, 2008; Guyton, 1991). In a series of elegant studies, Lifton et al showed 
direct evidence of powerful capacity of renal excretory system in blood pressure 
regulation by conducting genetic studies in humans. These investigators showed 
that all Mendelian disorders having major impact on blood pressure regulation 
are caused by genetic variants affecting water and salt reabsorption by renal 
distal tubule (Lifton, Gharavi, & Geller, 2001).  
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Kidney transplantation studies in animal models strongly support the 
concept that kidney plays inextricable role in hypertension. For example, a 
normotensive recipient of renal graft from genetically hypertensive donor 
develops posttranslational hypertension (Crowley et al., 2005). These types of 
transplantation experiments with similar results have been performed at least in 
four different animal models. Moreover, when genetically hypertensive rats 
having bilateral nephrectomy receive kidney from normotensive rats show 
reduced arterial pressure. Similar results have been reported in clinical studies 
showing that a normotensive patient receives renal graft from a donor with a 
genetic predisposition to hypertension, develops high blood pressure. These 
transplantation studies support the concept of kidney playing a primary role in 
initiating essential hypertension (Navar, 2005).  
 Renin angiotensin system (RAS) 2.2.1.
About a century ago in 1989, Robert Tigerstedt and Per Bergman discovered that 
extract from the kidney cortex produces consistent pressure effect when injected 
intravenously in rabbits. They termed the substance ‘renin’ (Phillips & Schmidt-
Ott, 1999). This study laid the foundation of Renin Angiotensin System (RAS) 
which is now considered one of the most complex pathways, and the master 
regulator of blood pressure and fluid homeostasis (Crowley & Coffman, 2012). 
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This system involves two important enzymes, renin and angiotensin-converting 
enzyme (ACE). Renin cleaves angiotensinogen, main substrate, into angiotensin 
I (Ang I) which is converted into angiotensin II (Ang II) by ACE. Notably, Ang (1-
12), a product of angiotensinogen, is also cleaved to Ang II largely by chymase in 
the human heart. Although, appropriate activation of RAS system is indispensible 
in regulating normal circulatory homeostasis, abnormal activation of RAS has 
been implicated in hypertension and target organ damage. The importance of 
RAS system in clinical medicine can be seen by the impressive and specific 
efficacy of pharmacological agents such ACE inhibitors and AT1 receptor 
blockers that inhibit the synthesis and function of Ang II respectively resulting in 
reduced blood pressure (Lewis, Hunsicker, Bain, & Rohde, 1993; Pfeffer et al., 
1992). Also, Inhibition of RAS system helps protect target organ damage.  
            At the cellular levels, Ang II produces its effect by activating angiotensin II 
type 1, (AT1) and type 2 (AT2) receptors. These two subtypes of receptors have 
been classified based on their differential affinities towards various non-peptide 
antagonists. These studies suggest that most of the classically recognized 
functions of the RAS system are mediated by AT1 receptor (Timmermans et al., 
1993). Moreover, elegant gene-deletion studies by Crowley et al confirms this 
(Crowley, Tharaux, Audoly, & Coffman, 2004).  
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              Distinct role of renal RAS has been established in regulating blood 
pressure. Hall et al. in 1980s, in a series of elegant articles reported that chronic 
infusion of low dose of angiotensin II into kidney causes hypertension due to 
impaired pressure-natriuresis relationship (Hall, 1986). Moreover, Navar and 
associates postulated that kidney possesses its independent RAS system to 
regulate Na excretion and blood pressure regulation (Kobori et al., 2007). This 
group showed that Ang II by activating renal AT1 receptor activates local RAS in 
the kidney resulting in increased synthesis of Ang II in the lumen of renal tubules 
and thus activates paracrine and autocrine epithelial transporters (Navar, 
Harrison-Bernard, Wang, Cervenka, & Mitchell, 1999; Navar, Lewis, Hymel, 
Braam, & Mitchell, 1994). Most importantly, elegant and uniquely designed 
studies of kidney cross-transplantation studies in rat by Crowley and Coffman 
group clearly demonstrate the imperative role of renal RAS in sodium balance 
and blood pressure regulation (Coffman & Crowley, 2008; Crowley et al., 2005).  
 Angiotensin II receptors 2.2.2.
AT1 receptor is a G protein coupled receptor expressed ubiquitously in all 
tissues. It has seven transmembrane domains, which are extra-cellularly 
connected to three N-terminus and intra-cellularly with three C-terminus loops. 
Extracellular loop and transmembrane domain provide the binding site for Ang II. 
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C-terminus of AT1 receptor is linked to internalization, desensitization and 
phosphorylation of AT1 receptor. Human AT1 receptor shares 97% homology 
with rodent and bovine AT1 receptors. 
 
Figure 2. Detailed amino acid sequence of AT1 receptor with antibody 
binding site. 
(de Gasparo et al., 2000). 
Although AT1 receptor is expressed ubiquitously, its predominant 
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expression is found in the key organs such as heart, kidney, blood vessels, 
adrenal glands and cardiovascular control system in the brain (Shanmugam & 
Sandberg, 1996). Activation of AT1 receptor in the vascular system causes 
potent vasoconstriction. In adrenal cortex, their activation causes the release of 
aldosterone that increases reabsorption of sodium in renal distal tubule. Renal 
AT1 receptor activation results into reduced natriuresis and increased renal 
vasoconstriction. In the brain, injection of Ang II into ventricular area causes 
sudden increases in pressure response mediated by AT1 receptor.  
            Relative contributions of AT1 receptors in different tissues to control blood 
pressure and pathophysiology of hypertension are difficult to dissect. A kidney 
cross-transplantation study using wild-type and AT1 receptor deficient mice 
showed non-redundant and equal contribution of renal and systemic tissues AT1 
receptors in the regulation of blood pressure, suggesting that AT1 receptors of 
systemic tissues play equally important role in maintaining body fluid volume and 
thus protect body from circulatory collapse (Crowley et al., 2005). In contrast, 
another study using cross-transplantation approach showed that AT1 receptors 
in the kidney plays dominant role in causing hypertension by promoting sodium 
retention and high blood pressure (Crowley et al., 2006). Coffman and group 
recently performed conditional deletion of AT1 receptor in the epithelium of renal 
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proximal tubules (RPTs) and suggested that AT1 receptors in proximal tubule are 
critical in maintaining blood pressure and Ang II dependent pathogenesis of 
hypertension. Sodium transporters including NHE3 sodium-proton transporter in 
RPTs are implicated for this activity (Gurley et al., 2011). Some studies have 
suggested that Ang II via AT1 receptor modulate solute and fluid reabsorption in 
the distal nephron (Peti-Peterdi, Warnock, & Bell, 2002; Stegbauer et al., 2011). 
Moreover, some studies indicated that urine-concentrating mechanism is 
determined by AT1 receptor present in the collecting duct. To confirm this 
mechanism, AT1 receptors were deleted from collecting duct in mice using Cre-
LoxP technology. These mice exhibit consistent lower urine osmolality following 
water deprivation or vasopressin infusion. Also, levels of aquaporin-2 (AQP2) 
protein in inner and outer medulla were significantly reduced in water-deprived 
mice, but localization to apical membrane was unchanged. This study suggests 
that AT1 receptors in collecting duct directly affect water reabsorption by 
modulating the levels of AQP2 and thus play an important role in achieving 
maximal urinary concentration (Stegbauer et al., 2011).  Activation of AT1 
receptor causes activation of G protein dependent and independent signaling 
pathways. Activation of AT1 receptor stimulates phospholipase C (PLC), 
phospholipase A2 (PLA2) and phospholipase D (PLD) that generates IP3/Ca2+ 
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and diacylglycerol (DAG), arachidonic acid/leukotrienes and phosphatidic acid, 
respectively. Activation of these diverse molecules induces myriad of 
downstream signaling pathways. These pathways have been implicated in cell 
survival, migration, hypertrophy, endothelial dysfunction, contraction, fibrosis and 
thrombosis. These pathways have been shown to recruit key signaling proteins 
such as Ras, mitogen-activated protein kinases (ERK ½, P38 MAPK, and stress 
activated protein kinase), tyrosine kinases, receptor tyrosine kinases (EGFR, 
PDGFR, IGF) and nuclear factor kappa (NF-κ) B. Although, AT1 receptor in most 
of the tissues is mainly coupled with Gαq/11 protein resulting in inducing 
PLC/PKC signaling, this receptor also couples to Gαi/o, and Gα 12/13 in some 
organ tissues (de Gasparo et al., 2000). Notably, activation of AT1 receptor 
induces the activation of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase. This enzymes is considered one of the major sources of ROS that 
activates pro-inflammatory transcription factors and small G proteins such as 
Ras, Rac and RhoA (Ushio-Fukai et al., 1999). Also, AT1 receptor stimulation 
activates β-arrestin and Src-JAK-STAT signaling pathways independent of G 
proteins (DeWire, Ahn, Lefkowitz, & Shenoy, 2007). 
 Regulation of AT1 receptor gene expression 2.2.3.
Studies in others and ours labs have established a direct link between 
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oxidative stress and hypertension (Chugh, Lokhandwala et al. 2011, Chugh, 
Lokhandwala et al. 2012). For example, recent studies in our lab demonstrated 
that oxidative stress plays a causal role in hypertension in FBN rats because 
treatment with antioxidant tempol resulted in reduced both oxidative stress and 
high blood pressure. Moreover, this study also showed that renal AT1 receptor is 
involved in contributing to hypertension because treatment with AT1 receptor 
blocker candesartan results in increased natriuresis and diuresis in FBN rats 
(Chugh et al., 2011, 2012). Pioneering work by Guyton and colleagues 
established kidney as a primary organ in blood pressure regulation and 
electrolyte homeostasis. Moreover, recent elegant studies from the groups like 
Crowley and Coffman, Navar, and Hall corroborated and confirmed that renal 
AT1 receptor plays a unique and non-redundant role in regulating blood 
pressure, and fluid and electrolyte homeostasis (Crowley et al., 2005; Hall, 1991; 
Navar, Prieto, Satou, & Kobori, 2011). Furthermore, Gurley et al recently 
demonstrated that AT1 receptor in the epithelium of renal proximal tubules are 
critical in maintaining blood pressure and Ang II dependent pathogenesis of 
hypertension (Gurley et al., 2011). This study suggests that AT1 receptor in renal 
proximal tubule is cardinal in regulating blood pressure and its hyper-activation 
contributes to hypertension, chronic kidney disease, and tissue damage. 
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However, molecular mechanism of renal AT1 receptor regulation is largely 
unknown. 
           Over the years, numerous studies have suggested that myriad 
physiological and pathophysiological factors regulate the expression of AT1 
receptor in different cells and tissues (Elton & Martin, 2007). Although molecular 
mechanism of AT1 receptor gene expression is not well known, a number of 
stimuli have been shown to modulate its expression. Ang II, interferon-γ, growth 
factors, tumor necrosis factor (TNF)-α, thyroid hormone, NO, and peroxisome 
proliferator-activated receptor (PPAR)- γ are some important stimuli that have 
been shown to suppress AT1 receptor gene expression in cultured cells from rat. 
On the other hands, interleukin (IL)-6, glucocorticoids, insulin-like growth factor 
and prostaglandin have been shown to increase the expression of AT1 receptor. 
Sp3 transcription factors has been shown to regulate basal expression levels of 
AT1 receptor gene in rodents and humans (Kubo, Kinjyo, Ikezawa, Kambe, & 
Fukumori, 2003). However, role of Sp3 transcription factor in the up-regulation of 
AT1 receptor expression and function has not been elucidated yet.  
2.3. Specificity protein (Sp) transcription factors family 
Specificity protein (Sp) transcription factors are members of Sp/kruppel-like factor 
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family. Nine different Sp (Sp1-Sp9) proteins have been identified which share 
highly conserved three zinc finger DNA-binding domains at the C-terminus, the 
adjacent Button-head box (btd-box) and the N-terminal Sp-box. These proteins 
play an important role in embryonic and early postnatal development and are 
extensively studied in the field of cancer research (Safe, Imanirad, Sreevalsan, 
Nair, & Jutooru, 2014). Sp1 and Sp3 are two important Sp family members, 
which are expressed ubiquitously and are structurally and evolutionarily closely 
related and found to be bound to GC and GT rich DNA motifs with similar affinity 
and specificity (Hagen, Muller, Beato, & Suske, 1992). However, gene deletion 
studies suggest that functionally these two proteins are different from each other 
(Kruger et al., 2007). For example, while, Sp1 homozygous knockout mice die in 
early embryonic development (E10.5 days) (Marin, Karis, Visser, Grosveld, & 
Philipsen, 1997), Sp3 homozygous knockout mice develop till pregnancy but die 
immediately after birth due to respiratory failure. In addition, Sp3 knockout mice 
exhibit distinct defect in late teeth formation and skeleton ossification (Bouwman 
et al., 2000). Also, Sp3 null mice show defect in erythroid and myeloid cell 
lineage differentiation.  
Sp1 and Sp3 are ubiquitously expressed in mammalian cells, but Sp2 and 
Sp4 expression is restricted only to certain tissues. For example, Sp4 is highly 
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expressed in central nervous system and retinal neurons (Lerner, Peng, 
Gribanova, Chen, & Farber, 2005), Sp2 is expressed in certain cell lines and 
cancer cells (Phan et al., 2004). A number of studies including in our own lab 
have reported that Sp3 is a redox-sensitive transcription factor and high levels of 
ROS modulate its activity (Banday & Lokhandwala, 2015; Jutooru et al., 2014; 
Lee et al., 2006; Nair et al., 2014; Schafer et al., 2003).  
 Modular structure of Sp proteins family 2.3.1.
 Sp proteins possess distinct sub-domains each performing specific functions (L. 
Li, He, Sun, & Davie, 2004). Sp1 and Sp3 both contain two sub-domains A and 
B, which are called transactivation domain, each of which can stimulate 
transcription of gene. Button-head box is present in both Sp1 and Sp3 within C 
domain, which may contribute to their transcription potential. There are three 
Cis2-His2 zinc “fingers” at carboxyl-terminal of C sub-domain. These zinc fingers 
help the transcription factors bind to the specific DNA promoter motifs rich in GC 
content. Sp3 contains an inhibitory domain within C sub-domain in front of the 
zinc finger, while inhibitory domain for Sp1 is located at N-terminus. The 
difference in the location of inhibitory domains is believed to be responsible for 
the factors’ distinct functions (Suske, 1999). Post-synthetic modification of Sp3 
makes this protein more complex (Sapetschnig, Koch, Rischitor, Mennenga, & 
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Suske, 2004). 
  
Figure 3. Structural domains of Sp1 and Sp3. 
Amino acid length and molecular mass of the Sp1 and Sp3 isoforms are 
indicated on the right. Colors for Sp box, buttonhead (BTD) box, zinc-finger 
domain, highly charged region, serine/threonine (S/T)-rich, and glutamine (Q)-
rich domains are shown at the bottom. The black bars marked with A, B, C, and 
D denote the sub-domains. Sp3 long forms (L1- and L2-Sp3) and short forms 
(M1-, M2-Sp3) are indicated. AD, activation domain; ID, inhibitory domain. 
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 Sp3 isoforms 2.3.2.
Four isoforms of Sp3 protein have been identified so far, two long (L1-Sp3, L2-
Sp3) and two shorts (M1-Sp3, M2-Sp3) that are the products of differential 
translational initiation sites of their mRNA (Sapetschnig et al., 2004). Long 
isoform of Sp3 protein is structurally very similar to that of Sp1, except the 
position of repression domain (Suske, 1999). The long and short isoforms of Sp3 
are expressed in all mammalian cells. The short isoforms of Sp3 lack the 
activation domain A but possess the activation domain B and the inhibitory 
domains.  
 Synergism in Sp protein family 2.3.3.
Sp1 is the perfect example of synergism in Sp family. This protein in 
promoters containing multiple Sp-binding sites exerts its transcription synergism 
through direct protein-protein interaction (Mastrangelo, Courey, Wall, Jackson, & 
Hough, 1991; W. Su, Jackson, Tjian, & Echols, 1991). However, Sp3 does not 
possess the synergism characteristic as demonstrated in in vitro studies (Yu, 
Datta, & Bagchi, 2003). Sp3 binds as a monomer while Sp1 binds as a multiplier 
on a single Sp1 binding site.  Several studies have also reported that Sp3 
competes with Sp1 for binding on gene promoters containing multiple Sp1 
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binding sites and as a result efficiently represses Sp1-dependent transcription. 
However, some reports suggest that Sp3 may synergistically potentiate some 
Sp1-dependent promoters. These and others reports suggest that the repressive 
function of Sp3 is gene promoter context dependent (L. Li et al., 2004).  
 Protein interactions with Sp3 2.3.4.
Sp3 directly or indirectly binds with different transcription factors, 
transcriptional regulators, and chromatin remodeling factors [e.g. estrogen 
receptor (ER) α, HDAC1, p300/CBP, SWI/SNF, an ATP-dependent chromatin 
remodeling complex] to activate or repress the expression of genes (Li, He et al. 
2004). Co-immunoprecipitation and indirect immunofluorescence of Sp3 
demonstrated that Sp3 associate with HDAC (histone deacetylase)-1 and 
HDAC2 as well as with ERα in MCF-7 cells (He, Sun, Li, & Davie, 2005). Sp3 
acts as a transcriptional repressor protein by recruiting the Sin3A 
HDAC1/HDAC2 complex and binding to RbAp48 and/or Sin3A (Clem & Clark, 
2006), while it acts as a transcriptional activator by recruiting CBP and p300 co-
activators. CBP and p300 possess potent histone acetyltransferase (HAT) 
activity and function as co-activators (Ammanamanchi, Freeman, & Brattain, 
2003). Studies reported that estrogen can form complexes with ERα, Sp1 or Sp3 
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and can induce the expression of estrogen responsive genes (He et al., 2005). 
On the other hand, repression can be achieved by perturbing the interaction 
between Sp1/Sp3 and the basal transcription initiation complex (Zhang & Dufau, 
2003). These studies suggest that Sp3 can recruit and form complexes with 
different proteins, which can cause region specific changes in histone acetylation 
and recruitment of RNA polymerase II within promoters and consequently 
activate or repress gene expression.  
 Sp-protein family and cancer 2.3.5.
Sp-family of transcription factors plays a key role in cell cycle regulation and 
tissue development. Sp1/Sp3 and other members of this family are over-
expressed in various human cancers (Safe & Abdelrahim, 2005). Sp1/Sp3 can 
bind to the same sites on the oncogene c-myc promoter and other pro-oncogenic 
genes. One of the mechanisms linking Sp-proteins with cancer suggests that 
microRNAs regulate the expression of transcriptional repressors such as 
ZBTB10, ZBTB34 and ZBTB4. In cancer cell lines, expression of Sp1 and Sp3 
proteins has been linked to microRNA-dependent regulation of these repressors. 
These repressors competitively bind to Sp-protein binding sites (GC-rich DNA 
motifs) at the promoters and repress transcriptional activity of the genes. Recent 
studies suggest that microRNA 27a (miR-27a) represses the expression of 
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ZBTB10 while miR-20a and miR-17-5-p repress the expression of ZBTB4 (K. Kim 
et al., 2012). High levels of ROS (termed oxidative stress) are shown to decrease 
the expression of miR-27a/miR- 20a:miR-17-5p and thus induces the miR-
regulated transcriptional repressors ZBTB10, ZBTB4 and ZBTB34 resulting in 
down-regulation of Sp proteins (Vizcaino, Mansilla, & Portugal, 2015). This 
pathway has been exploited to develop a number of anticancer drugs.   
 Sp3 protein and AT1 receptor expression 2.3.6.
Although, Sp3 transcription factor and renal AT1 receptor individually have 
extensively been studied over the years for gene regulation and blood pressure 
regulation respectively, only a few studies reported that Sp3 transcription factor 
regulates AT1 receptor. Zhao et al showed that Sp1/Sp3 are required for basal 
expression levels of AT1 receptor in H295-R cells (Zhao, Martin, & Elton, 2000, 
2001). Moreover, Kambe et al showed that Sp1 protein levels were high in 
hypothalamic cells and inhibition of Sp1 with decoy phosphorothioate 
oligodeoxynucleotides decreases AT1 receptor expression and blood pressure in 
SHR (Kubo et al., 2003) suggesting that this family of proteins might be 
regulating blood pressure by modulating AT1 receptor expression. Also, one 
more report from the same lab demonstrated that Sp1/Sp3 regulate AT1 receptor 
expression in a vascular smooth 
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muscle cell line, A10 cells (Kambe et al., 2004).  
2.4. NF-κB p-65 transcription factor and AT1 receptor expression 
Nuclear factor-kappa B (NF-κB) protein is a transcription factor, which was first 
described by H. Singh, R. Sen and D. Baltimore in 1980s (R. Sen & Baltimore, 
1986b; Singh, Sen, Baltimore, & Sharp, 1986). It plays an important role in the 
regulation of innate immunity, cell growth and apoptosis, and inflammatory 
responses (Atchison & Perry, 1987; X. C. Li & Zhuo, 2008; R. Sen & Baltimore, 
1986a). An inhibitory IκB protein binds to NF-κB in the cytoplasm and thus 
inhibits its activity. Upon stimulation of the cell, IκB protein gets serine-
phosphorylated and degraded, resulting in releasing active NF-κB protein that 
translocates to the nucleus and activates a myriad of genes including genes 
involved in cancer, cell growth and apoptosis, innate immunity and inflammatory 
diseases (Hayot & Jayaprakash, 2006; Stancovski & Baltimore, 1997). Studies in 
others and ours labs have shown that NF-κB is a redox-sensitive transcription 
factor and contribute to hypertension that impairs renal D1 receptor and AT1 
receptor functions and contributes to hypertension (Bhatt et al., 2014; Elton & 
Martin, 2007; Mitra, Gao, & Zucker, 2010). Also, NF-κB is implicated in diseases 
like asthma, muscular dystrophy, and hypertension. However, some labs 
including ours suggested that this transcription factor plays an important role in 
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up-regulating antioxidants enzymes and protects cells against oxidant damage 
(L. George et al., 2009; L. E. George et al., 2012). These important and diverse 
functions make NF-κB one of the most studied transcription factor in biology and 
related areas.   
Numerous studies have shown that oxidative stress activates NF-κB and 
causes its translocation to nucleus where it binds to AT1 receptor promoter and 
contributes to hypertension (Banday et al., 2007; Barchowsky, Munro, Morana, 
Vincenti, & Treadwell, 1995; Bhatt et al., 2014; Toledano & Leonard, 1991). 
Several studies including in our own lab have demonstrated that AT1 receptor 
gene possesses the consensus sequence for NF-κB binding (Bhatt et al., 2014; 
Heinemeyer et al., 1998). However, link between oxidative stress, NF-κB 
transcription factor, and AT1 receptor is missing. Therefore, we try to investigate 
the role of oxidative stress mediated NF-κB transcription factor and its role in 
renal AT1 receptor up-regulation HK2 cells.   
2.5. Reactive oxygen species (ROS) 
 Classification of ROS 2.5.1.
Reactive oxygen species (ROS) is a collective term for free radicals such as 
superoxide, hydroxyl radical, and alkoxy radicals and non-radicals such as 
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hydrogen peroxide (H2O2), peroxynitrite, and hypochlorous acid (Harrison & 
Gongora, 2009). All ROS are products of oxygen metabolism, which can 
sequester electrons from other molecules (oxidize), donate electrons to 
molecules (reduce) or react with and become part of other molecules (oxidative 
modification). Superoxide is particularly important in cardiovascular biology due 
to the fact that it can serve both as an oxidant and as a reductant and can 
generate other ROS. Reactive nitrogen species (RNS), another relevant group, 
includes nitric oxide (NO), nitrogen dioxide radical (NO2), and nitrosonium cation. 
Peroxynitrite is considered both as ROS and RNS due to its formation from 
superoxide and nitric oxide (Paravicini & Touyz, 2006). 
 Production  2.5.2.
Oxygen radicals or ROS can be generated by electron-transfer and or energy 
transfer reactions as shown in boxes below.  
 
Below is the schematic illustration of ROS formation by sequential electron 
transfer mechanism. 
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The addition of a single electron to molecular oxygen forms superoxide 
anion radical. Addition of two electrons to molecular oxygen or one electron to 
superoxide results into the formation of H2O2. It is noteworthy that superoxide is 
an intermediate molecule in the formation of H2O2 from univalent reduction of 
molecular oxygen. The reaction between superoxide and H2O2 generates 
hydroxyl radical, which is the most reactive ROS in the biological system. 
Chemically, addition of one electron to H2O2 results into the formation of hydroxyl 
radical and water. 
             There are a number of sources of ROS in biological systems including 
enzymes, various types of cells, chemicals, and environmental factors. Xanthine 
oxidase, nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, 
NADPH-cytochrome P450 reductase, and, under certain conditions nitric oxidase 
are the key enzymes that are implicated in the generation of ROS. These 
enzymes get activated in various disease conditions including atherosclerosis, 
hypertension, diabetes and renal diseases. Importantly, these enzyme systems 
can interact with one another, such that ROS produced by one enzyme can 
activate others.  For example, peroxynitrite can oxidize tetrahydrobiopterin, a 
critical co-factor for nitric oxide synthase, which causes the uncoupling of nitric 
	  	  
	  
	  
	  
	  
28	  	  
	  
	  
	  
oxide synthase (NOS), which as a result produces superoxide instead of nitric 
oxide (Munzel, Daiber, Ullrich, & Mulsch, 2005). In addition to enzymes, 
leukocytes and macrophages, mitochondrial electron transfer system, and 
microsomal monooxygenases are cellular sources of ROS. Ultraviolet light, X-
rays, toxic chemicals, pesticides such as paraquat, and chemotherapeutic agents 
such as quinones are some of the environmental sources of ROS.  
              Although earlier ROS used to be considered toxic by-product of cell 
metabolism, recently these have been established as a key signaling molecules 
in normal cellular functions including growth, remodeling, apoptosis, and 
migration (Harrison & Gongora, 2009). For example, H2O2 has been established 
as an endothelial-derived hyperpolarizing factor involved in maintaining vascular 
tone (Miura et al., 2003). The following quote attributed to Hans Selye might well 
apply to the concept of oxidative stress: “If only stress could be seen, isolated 
and measured, I am sure we could enormously lengthen the average human life 
span” (Sies, 2015).  
 ROS, kidney and hypertension 2.5.3.
Oxidative stress is a state when there is an imbalance between ROS 
producing systems and anti-oxidative defense mechanism of the body. Higher 
	  	  
	  
	  
	  
	  
29	  	  
	  
	  
	  
activity of either ROS producing and/or lower activity of antioxidant defense 
systems can cause a state of oxidative stress. A large body of evidence suggests 
that elevated levels of ROS contribute to hypertension in animal models. 
Scavenging ROS using different approaches attenuated hypertension in animals 
model, suggesting ROS are a contributing factor in causing hypertension 
(Nakazono et al., 1991).  Moreover, a number of studies have shown high levels 
of oxidative stress in the kidneys of hypertensive animals suggesting their role in 
blood pressure. Several studies have shown virtually every cells in the kidney 
including vessels, glomeruli, podocytes, interstitial fibroblast, macula densa, 
medullary thick ascending limb (mTAL), the distal tubules, and the collecting 
ducts express NADPH oxidase (Chabrashvili et al., 2002). The main targets of 
oxidant stress include the proximal tubule, the afferent arteriole, the glomerulus 
and the cortical collecting duct. Importantly, superoxide in the afferent arteriole 
reduces the levels of nitric oxide (NO) resulting in increased vasoconstriction and 
reduced GFR. Studies both in whole animals and isolated afferent arteriole have 
shown that superoxide generated by NADPH oxidase causes endothelial 
dysfunction in afferent arteriole (Fellner & Arendshorst, 2005; Wang et al., 2003). 
Moreover, scavenging superoxide induces vaso-relaxation and improves kidney 
perfusion, thus alleviates hypertension (Kopkan, Castillo, Navar, & Majid, 2006). 
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Furthermore, Dahl salt-sensitive rats, a hypertensive rat model, exhibit 
overexpression of NADPH oxidase subunits nox4 and p22phox in glomerulus with 
podocyte injury. Superoxide scavenger tempol reduces proteinuria and 
glomerular sclerosis in these rats, further supporting the role of ROS, especially 
superoxide, in the glomerular injury (Meng, Cason, Gannon, Racusen, & 
Manning, 2003). 
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Figure 4. Schematic representation of a juxtamedullary glomerulus 
showing sites of ROS production and potential roles in sodium transport, 
reabsorption, and blood pressure regulation. 
D1, Dopamine type 1 receptor; GFR, glomerular filtration rate; mTAL, medullary 
thick ascending limb; Na, sodium; NO, nitric oxide (Harrison & Gongora, 2009). 
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Renal proximal tubular cells possess inactive NADPH oxidase especially in lipid 
rafts, which can be activated by either disrupting lipid rafts or application of Ang 
II. Recent studies have shown that ROS and NADPH oxidase modulate levels of 
sodium transport by altering the activity of Na/K ATPase and Na/H exchange 
present on basal and apical membranes, respectively, in proximal tubular cells 
(Banday et al., 2007; Banday, Lau, & Lokhandwala, 2008; Banday & 
Lokhandwala, 2008a). These studies demonstrated that Ang II and dopamine 
respectively stimulate and inhibit sodium transport. Also, these studies suggest 
that oxidative stress potentiates Ang II response while inhibits dopamine 
response, that results in increased sodium transport in proximal tubular cells. 
Challenging question is how oxidative stress affects proximal tubular cells and 
contributes to hypertension. One of the mechanisms is that ROS by modulating 
tubuloglomerular feedback may modulate sodium transport in the cortex and as a 
result controls blood pressure. For detailed description, please read (Liu, Ren, 
Garvin, & Carretero, 2004).  
ROS also modulate sodium transport in renal medulla that is implicated in 
blood pressure regulation. Medullary epithelial cells of mTAL and pericytes in the 
vasa recta equally contribute to the production of superoxide and nitric oxide. 
Comparative studies suggested that NO production in medulla is higher than that 
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of cortex, therefore, it is likely that regulation of cortex and medulla is 
independent of each other ((Wu, Park, Cowley, & Mattson, 1999). Studies from 
Cowley et al. demonstrated that nitric oxide released by mTAL diffuses to nearby 
pericytes of adjacent vasa recta that in turn dilates these vessels. As a result, 
medullary and interstitial Starling flow are alleviated that in turn promotes sodium 
movement to the tubules and thus increasing natriuresis and diuresis (Cowley, 
Mori, Mattson, & Zou, 2003; Dickhout, Mori, & Cowley, 2002). Renal medullary 
cells also contain all components of NADPH oxidase that can be activated by 
locally or systemically produced Ang II that results into increased production of 
superoxide. Elevated levels of superoxide cause vasoconstriction of vasa recta 
and reduce Starling forces causing sodium movement into vasa recta, reduced 
natriuresis, and increased blood pressure (Mori & Cowley, 2003).  
In summary, it seems that normal levels of ROS play indispensible role in 
controlling renal physiology, while high levels of ROS have been implicated in the 
pathophysiology of a number of diseases including hypertension, atherosclerosis 
and other cardiovascular disorders. Importantly, sodium and water retaining 
quality of kidney during sodium-restricted diet is an extremely important function 
in terrestrial mammals, without which survival would be impossible. It is likely that 
superoxide and other ROS are generated in the terrestrial mammals to maintain 
	  	  
	  
	  
	  
	  
34	  	  
	  
	  
	  
sodium and water balance.  
 Oxidative stress in animal models of hypertension 2.5.4.
A number of hypertensive animal models including genetic forms (SHR, 
stroke-prone SHR), endocrine induced (Ang II, and deoxycorticosterone acetate), 
experimental pulmonary hypertension (Dorfmuller et al., 2011), and aging Fisher 
344 X Brown Norway (FBN) (Chugh et al., 2011) rat models exhibit high level of 
oxidative stress. It is reported that oxidative stress does fetal programming in 
SHR to cause hypertension because in this rat model oxidative stress precedes 
the development of hypertension. Experimental hypertensive rats exhibit reduced 
levels of antioxidant enzymes and NO, increased activation of xanthine oxidase, 
NADPH oxidases and other ROS generating enzymes, elevated organ tissue 
levels of superoxide and H2O2, and increased levels of oxidative stress markers 
such as 8-isoprostane, thiobarbituric acid reactive substances. Evidence for 
oxidative stress as a contributing factor in hypertension, several studies have 
demonstrated that antioxidants SOD mimetic [tempol, (4- hydroxy-2,2,6,6-
tetramethyl piperidinoxyl)], vitamins (A and E), and tetrahydrobiopterin attenuate 
or prevent hypertension in hypertensive animal models (Raijmakers, Dechend, & 
Poston, 2004; Rey, Cifuentes, Kiarash, Quinn, & Pagano, 2001; Wilcox, 2010).  
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 Oxidative stress and hypertension in humans 2.5.5.
Although, there is ample experimental evidence supporting the causative role of 
oxidative stress in human hypertension, no single study confirms that oxidative 
stress is the primary cause of hypertension in humans. In spite of that, patient 
with essential hypertension, malignant hypertension, cyclosporine-induced 
hypertension, reno-vascular hypertension, pre-eclampsia, and salt-sensitive 
hypertension exhibit higher levels of ROS (K. Chen et al., 2011; Raijmakers et 
al., 2004; Rodrigo et al., 2007; Ward et al., 2004). Most of the clinical studies 
showed increased levels of oxidative stress biomarkers such as lipid peroxidation 
thiobarbituric acid reactive substances and 8-epi-isoprostane (K. Chen et al., 
2011; Murphey et al., 2003). Also, levels of superoxide generated by 
polymorphonuclear leucocyte and platelet are increased in hypertensive patients 
(Yasunari, Maeda, Nakamura, & Yoshikawa, 2002).   
            Patients with hypertension exhibit increased production of plasma H2O2 
than normotensive persons.  Moreover, normotensive persons with family history 
of hypertension exhibit higher production of H2O2 than the blood pressure-
matched normotensive persons without a family history of hypertension. This 
study suggested that genetic component might be involved in H2O2 production 
(Lacy, Kailasam, O'Connor, Schmid-Schonbein, & Parmer, 2000; Lacy, 
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O'Connor, & Schmid-Schonbein, 1998). Vascular smooth muscle cells of 
resistant artery from hypertensive patients show increased activity of NADPH 
oxidase and ROS production.  
               Low levels of antioxidants have been shown to contribute to oxidative 
stress in patients with hypertension. These patients show reduced levels and 
activity of antioxidant enzymes such as SOD, catalase, and glutathione 
peroxidase. Lower levels of vitamins A, C, and E have also been reported in 
untreated hypertensive patients. Additionally, there exists an inverse relationship 
between SOD activity and blood pressure in hypertensive patients. Further, 
support for a role of oxidative stress in hypertension comes from a study that 
reported increased levels of serum protein carbonyls (an indicator of protein 
oxidation), and reduced levels of enzymatic antioxidants in patients with white 
coat hypertension compared with normotensive persons (Caner et al., 2006).  
 Molecular and cellular mechanisms of oxidative stress in 2.5.6.
hypertension 
At cellular level, mechanism of ROS induced hypertension involves activation of 
redox-sensitive signaling pathways, particularly in the vascular system. In the 
vasculature, increased ROS, particularly superoxide and H2O2, reduced the 
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levels of vasodilator NO and causes vasoconstriction and contributing to 
hypertension. In addition, ROS are implicated in activating various redox-
sensitive transcription factors including NF-κB, Sp3, HIF-1 and AP-1, inactivating 
protein tyrosine phosphatases (PTP), and increasing intracellular free calcium 
concentration ([Ca2+]i). Furthermore, ROS are implicated in the overexpression of 
proto-oncogenes and inflammatory genes (Al Ghouleh et al., 2011; Banday & 
Lokhandwala, 2015; Droge, 2002; Zinkevich & Gutterman, 2011). These changes 
in intracellular signaling may cause endothelial dysfunction, increased 
constriction, reduced vasodilation, and structural remodeling of vasculature that 
results in increased peripheral resistance and hypertension (Touyz & Briones, 
2011). In the kidney, activation of redox-sensitive pathway is implicated in 
sodium and water retention, glomerular damage, proteinuria, and nephron loss, 
all of which are associated with the development of hypertension (Wilcox, 2005).   
 Antioxidants against oxidative stress  2.5.7.
Antioxidants are agents that at low concentrations prevent or inhibit the oxidation 
of biomolecules such as DNA, lipid, and protein by scavenging elevated levels of 
ROS. A number of defense systems have evolved in biological system to 
scavenge elevated levels of ROS. These are enzymatic, non-enzymatic, and 
external antioxidants, which show beneficial and protective effect against 
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oxidative damage caused by ROS. Superoxide dismutase (SOD), catalase, 
glutathione peroxidase, thioredoxin, and peroxiredoxin are main enzymatic 
antioxidants (Gongora et al., 2006).  While ascorbic acid, tocopherol, glutathione, 
bilirubin, and uric acid constitute non-enzymatic antioxidants (X. Chen, Touyz, 
Park, & Schiffrin, 2001). Low bioavailability of antioxidants results in cellular 
oxidative damage that has been implicated in cardiovascular and renal tissue 
damage and hypertension. It is reported that patients with hypertension exhibit 
lower activity of SOD, catalase, and glutathione peroxidase and higher levels of 
oxidized and reduced glutathionein plasma and circulating cells (Redon et al., 
2003). 
            Superoxide is a substrate for SOD, which converts it into H2O2 and O2. 
There are two types of SOD: manganese (Mn) SOD is present in mitochondrial 
matrix while copper/zinc Cu/Zn) SOD is present in cytosol, mitochondrial inter-
membrane and extracellular spaces (Miriyala et al., 2012). Extracellular SOD or 
Cu/Zn SOD is important as it determines oxidative status in the vascular 
interstitium. In addition, SOD prevents the formation of peroxynitrite by inhibiting 
the inactivation of NO, thereby helps maintains the endothelial function (Fukai & 
Ushio-Fukai, 2011). Catalase mainly resides in peroxisome and catalyzes H2O2 
into water and O2 and thus protects cellular damage arising from H2O2. 
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Glutathione peroxidase also converts H2O2 into water and O2 and helps protect 
cellular injury from H2O2 (Goyal & Basak, 2010). 
             Vitamin E, vitamin A and glutathione are major non-enzymatic biological 
antioxidants. Vitamin E (tocopherols and tocotrienoles) is the lipid-soluble while 
vitamin C (ascorbic acid) is water-soluble antioxidant, which is involved in 
scavenging radicals generated by oxidation of vitamin E. Vitamins C and E, at 
high concentrations, function as pro-oxidants that can be damaging to the cell. A 
number of clinical trials have attributed the negative impact of these vitamins on 
cardiovascular physiology (Montezano & Touyz, 2012).  
              Carotenoids, uric acid and bilirubin are small-molecules that function as 
biological antioxidants. Carotenoids are naturally occurring lipophilic compounds 
with β-carotene being present abundantly. These compounds possess 
conjugated double bonds, which are attributed for their antioxidant capacity. 
Bilirubin by inhibiting lipid oxidation and free radical formation may act as 
antioxidants and provide protection against cardiovascular disorders. Studies 
have suggested bilirubin as a potential clinical biomarker for cardiovascular 
diseases because clinical studies showed a clear inverse relationship between 
bilirubin levels and cardiovascular risk factors such as hypertension, diabetes 
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and metabolic disorders (Nagao, 2011).  
             A number of animal studies and a few small clinical trials have shown 
protective effect of antioxidant on cardiovascular diseases including 
hypertension. Therefore, much effort has been put into developing synthetic and 
naturally occurring antioxidants as therapeutic agents to prevent and/or treat 
patients with hypertension or related cardiovascular diseases. However, due to 
various reasons, many large clinical trials have failed to show protective effects 
of antioxidants in hypertensive humans (Kizhakekuttu & Widlansky, 2010). This 
indicates that a more focused study could be undertaken regarding role of 
antioxidants in combating hypertension and associated cardiovascular diseases 
in patients.  
 Why antioxidants may have failed in patients to treat hypertension 2.5.8.
As mentioned earlier, use of antioxidants to treat cardiovascular diseases 
including hypertension have been disappointing despite the promising results 
from animal studies. Reasons of failure may be multifold: (i) selection and dose 
of antioxidants, (ii) design of trials and, (iii) patient cohorts selected for the study. 
In these clinical trials, the dose and type of antioxidants was never demonstrated 
to reduce the levels of oxidative stress. In addition, several studies have shown 
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that vitamins C and E may act as pro-oxidants resulting in increase in oxidative 
stress-induced damage (Gori & Munzel, 2011). Moreover, either bioavailability of 
antioxidants with oral administration is not sufficient to scavenge ROS, or ROS 
generated in specific cellular organelles or compartments might not be 
inaccessible to antioxidants (Farbstein, Kozak-Blickstein, & Levy, 2010; 
Talaulikar & Manyonda, 2011). Importantly, antioxidants scavenge those ROS 
which are already generated and do not inhibit their production. There are no 
large clinical trials so far in which patients were included based on elevated 
oxidative stress levels. Also, these clinical trials were not specifically designed to 
study the effect of antioxidants on hypertension. It is worth mentioning here that 
there is no validated biomarker exists in the clinical setting that can verify that 
hypertensive patients have high oxidative stress and treatment with antioxidants 
reduces it. An analogy would be to test the effect of cholesterol-lowering drug for 
the treatment of coronary artery disease but without measuring cholesterol levels 
(Gori & Munzel, 2011).  
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3. MATERIAL AND METHODS 
3.1. Methods used in cell culture studies 
 Cell culture  3.1.1.
 Human Kidney (HK2) cells were purchased from American Tissue Culture 
Collection (ATCC® CRL-2190™, ATCC, Manassas, VA), cultured and used in 
the studies using our published methods (I. D. Pokkunuri, Chugh, & Asghar, 
2013). Briefly, cells were cultured in DMEM/F12 culture media supplemented 
with fetal bovine serum (FBS, 10% vol/vol), epidermal growth factor (EGF, 
5ng/ml), bovine pituitary extract (BPE, 50µg/ml), and cocktail of antibiotics and 
antimycotics in a humidified cell culture incubator maintained at 370C under 5% 
CO2. HK2 cells were grown up to 90-95% confluency, starved for 2 hr in 
DMEM/F12 media without FBS, BPE, and EGF before any treatments and used 
in the study unless otherwise stated. Cell passages between 4-17 were used.  
 Detection of superoxide and hydrogen peroxide in HK2 cells 3.1.2.
Levels of intracellular superoxide radicals were determined using cell permeable 
fluorescent probe, dihydroethidium [(DHE), Life technologies, Eugene, Oregon, 
USA]. Briefly, cells were grown, detached using trypsin/EDTA (0.5/0.2 g/L), 
suspended in Krebs-Henseleit (KH, pH 7.4) buffer and loaded in triplicate in a 96-
	  	  
	  
	  
	  
	  
43	  	  
	  
	  
	  
well transparent plate. Subsequently, 25µM DHE probe was loaded in each well 
and incubated for 5 min at room temperature. Thereafter, cells were treated with 
500µM SOD-inhibitor diethyldithiocarbamate (DETC) in the absence and 
presence of tempol, and 50µM H2O2 at room temperature and fluorescence 
intensity was recorded immediately using excitation (490 nm) and emission (610 
nm) wavelengths in a spectrofluorometer (Varioskan, Thermo Scientific, 
Rockford, IL, USA). Pre-treatment of tempol was carried out for 10 min before 
adding DETC and remained there in the reaction. DHE fluorescence was 
measured for 30 min at 5 min time-intervals and no significant difference among 
the readings was found. Data presented was at 5 min. 
Levels of intracellular H2O2 were determined using cell permeable 
DCFHDA probe (DCFHDA, Life technologies, Eugene, Oregon, USA). Briefly, 
cells were grown, detached using trypsin/EDTA (0.5/0.2 g/L), suspended in 
Krebs-Henseleit (KH, pH 7.4) buffer, and loaded in triplicate in a 96-well 
transparent plate. Subsequently, 10µM DCFHDA probe was loaded in each well 
and incubated for 30 min at room temperature. Thereafter, cells were treated with 
50µM H2O2 and DETC (500µM) for 30 min and with 10mM 3-amino-1,2,4-
triazole (3-AT, a catalase inhibitor), for 60 min. Subsequently, DCFHDA 
fluorescence intensity was recorded using excitation (490 nm) and emission (520 
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nm) wavelengths. 
 Toxicity measurement in DETC, H2O2, and tempol treated cells 3.1.3.
Toxicity was determined by a colorimetric assay using a commercially available 
kit (CellTiter 96® Aqueous One Solution Assay, Promega) and following 
manufacturer’s instructions. Briefly, adherent cells were treated with SOD-
inhibitor DETC (500µM) in the absence and presence of tempol (1mM), and H2O2 
(50µM) separately. Tempol was added 10 min before adding DETC. 
Subsequently, cells were detached using trypsin/EDTA (0.5/0.2 g/L), suspended 
in KH buffer, and loaded equally in triplicate in a 96-well transparent plate. 
Thereafter, CellTiter96® AQeous One Solution Reagent (20µl) was added to each 
well, and incubated for 2 h at 370C and absorbance was read at 490 nm. 
Absorbance is directly proportional to the number of viable cells.  
Moreover, trypan blue exclusion test was performed to determine the cell 
viability before conducting each experiment in HK2 cells (PMID: 3039859). 
Briefly, HK2 cells suspension was mixed with equal volume of trypan blue (0.15% 
in KHB) followed by monitoring trypan blue uptake by HK2 cells under 
microscope. Almost 90- 95% cells excluded trypan blue uptake suggesting 90-
95% cells were viable used in the study. 
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 Isolation of nuclear proteins 3.1.4.
Adherent cells were treated with DETC (500µM, 2 hr), H2O2 (50µM, 30 min) in 
the absence and presence of tempol (1 mM). Pre-treatment of tempol was 
carried out for 10 min before the addition of DETC and H2O2. Subsequently, cells 
were washed twice with cold PBS and detached using trypsin/EDTA (0.5/0.2 
g/L). Thereafter, cells were washed twice with media by centrifugation (300 g, 4 
min). Finally, cell palettes were used to isolate nuclear proteins using a 
commercial kit following manufacturer’s instructions (NE-PER kit, ThermoFisher 
scientific, Rockford, IL USA).  
 Cells transfections 3.1.5.
3.1.5.1 Sp3 plasmid and siRNA transfections 
Sp3 plasmid was a generous gift from Dr. Douglous A Weigent (University of 
Alabama, Birmingham, AL) that was used to overexpress Sp3 protein in HK2 
cells. A 2.3 Kb Sp3 construct was cloned into pCMV vector for the synthesis of 
Sp3 plasmid. FuGENE®6 (Promega Corp. Madison, WI) was used as the 
transfection reagent following manufacturer’s instructions. Briefly, cells were 
grown up to 65% confluency in a 6-well plate and transfected with 1 µg Sp3 
plasmid for 24 hr in a humidified cell culture incubator maintained at 370C under 
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5% CO2. Control cells were transfected with empty pCMV vector. For siRNA 
studies, cells were transfected with Sp3 siRNA (100 ng) for 24 hr. Control cells 
were transfected with Allstar control siRNA (Qiagen, Valencia, CA USA). 
Subsequently, cells were washed with PBS twice and lysed with lysis buffer 
(20mM tris-HCl pH 7.5, 150mM NaCl, 1mM EGTA, 2.5mM sodium 
pyrophosphate, 1mM beta-glycerophosphate, 1mM Na3VO4, 1mM PMSF and 
protease inhibitor cocktail) for 10 min on ice. Thereafter, cells were sonicated on 
ice for 3 sec, cell lysates obtained and used to determine the levels of Sp3 and 
AT1 receptor proteins by Western blotting.  
3.1.5.2 NF-κB plasmid and shRNA transfections 
An NF-κB p-65 plasmid in a pShooter vector (pEF/myc/nuc-NF-κB) with a nuclear 
translocation domain was used for the transfection. Briefly, cells were grown up 
to 65% confluency in a 6-well plate in antibiotic free media supplemented with 
FBS, transfected with 2 µg NF- κB p-65 plasmid for 24 hr. Control cells were 
transfected with pEF/myc/nuc (pShooter) vector (L. E. George et al., 2012). For 
NF-κB shRNA, cells were transfected with NF-κB shRNA (Santa Cruz 
Biotechnology) following manufacturer’s protocol. Briefly, control and NF-κB 
shRNA plasmids (each 10 µl) were mixed with transfection medium (90 µl) 
separately (solution A), In a separate tube 1 µl of transfection reagent (sc-
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108061) was mixed with 99 µl normal growth media (solution B). Thereafter, 
solutions A and B were mixed together, incubated for 30 min and used to 
transfect HK2 cells. Cell lysates were obtained as mentioned above and used to 
determine the levels of NF-kB and AT1 receptor proteins by Western blotting. All 
the experiments were conducted 24 hr post transfection. 
 Western blotting procedure  3.1.6.
Western blot was performed according to our published protocol (PMID: 
23698121). Cell homogenates, nuclear extracts, and membrane proteins (15-
20µg) were resolved on 8-16% Tris-glycine gels (ThermoFisher scientific, 
Rockford, IL USA) by SDS-PAGE and transblotted onto PVDF membranes for 
2.5 hr at 4oC. Subsequently, PVDF membranes were blocked with 5% BSA in 
TBST for 1 hr at room temperature (RT). Thereafter, membranes were washed 
with TBST thrice (each wash 5 min), and probed with respective primary 
antibodies in TBST overnight at 4 oC. After three washes with TBST, 5 min each, 
membranes were incubated with corresponding secondary antibodies conjugated 
with horseradish peroxidase (Santa Cruz Biotechnology). The protein bands 
were visualized with chemiluminescent reagent and quantified using G:BOX 
image station (Syngene, Frederick, MD) integrated software. Primary antibodies 
dilutions used were 1:500 for Sp3 and AT1 (both from SCBT, Dallas, TX), histone 
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3 and lamin B [(1:1000) nuclear protein loading control, Abcam, Cambridge, MA, 
USA)]. GAPDH (1:1000) (Millipore, Temecula, CA, USA) as protein loading 
control was used for cell homogenates. 
 AT1 receptor mRNA isolation and PCR 3.1.7.
Different drug treatments were carried out as mentioned in ‘isolation of nuclear 
proteins’ section. Following treatment, cellular mRNA was isolated and purified 
using Qiagen mini-kit following manufacturer’s protocol (Qiagen, Valencia, CA). 
As per the MIQE (Minimum Information for Publication of Quantitative Real- time 
PCR experiments) accepted guidelines, 1 µg total mRNA was reverse 
transcribed to cDNA using Advantage-RT-for-PCR kit (Clontech Laboratories, 
Mountain View, CA). Obtained cDNA was diluted 5 times and 9 µl of it was used 
for qPCR reaction. TaqMan human-specific primers for AT1 receptor 
(ID#Hs00258938-m1) and 18S ribosome internal control (ID# Hs99999901-s1) 
were purchased from Life Technologies (Grand Island, NY) and used in qPCR. 
The assay mixture consisted of 10 µl TaqMan® Gene Expression Master Mix, 1 
µl AT1 receptor or 18S ribosome TaqMan primers, and 9 µl of diluted cDNA in a 
final volume of 20 µl. Reactions were performed in Applied Biosystems® 7300 
Real Time PCR system using manufacturer’s software. AT1 receptor mRNA was 
quantified by relative quantification using Delta-Delta Ct method (I. Pokkunuri, 
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Chugh, Rizvi, & Asghar, 2015). 
 Immunofluorescence imaging 3.1.8.
 HK2 cells were grown to 70-80% on to glass-chambered slides (ThermoFisher 
scientific, Rockford, IL USA) and treated with DETC (500µM, 2 hr) in the absence 
and presence of tempol (1 mM).Control cells were treated with vehicle (water). 
Subsequently, cells were washed with cold PBS, fixed with formalin for 20 min 
and blocked with 5% normal goat serum (NGS in TBS) for 1 hr at RT. After 
washing with PBS, cells were incubated with rabbit AT1 receptor antibody that 
recognizes extracellular loop of AT1 receptor (1:500 in TBS) overnight at 4C. 
After washing with (TBS), cells were incubated with Alexa-488 conjugated goat 
anti-rabbit secondary antibody for 1 hr at RT in the dark. Cells were washed 
three times, each 10 min, with TBS and mounted with glass cover slips with DAPI 
mount media. Thereafter, the glass slides were dried overnight in the dark and 
scanned under a microscope (Olympus) using green filter and 20X objective.   
 
 Isolation of cell-surface proteins using biotin-streptavidin approach 3.1.9.
Cell surface proteins were cross-linked with EZ-LINK Sulfo-NHS-SS-biotin and 
isolated with streptavidin magnetic beads (ThermoFisher scientific, Rockford, IL 
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USA). Briefly, cells were treated with DETC (500µM, 2 hr) in the absence and 
presence of tempol (1 mM). Subsequently, cells were washed twice with cold 
PBS and immediately removed and incubated with EZ-LINK Sulfo-NHS-SS-biotin 
(250µg/ml) for 30 min at 4oC while shaking. Subsequently, 100 mM glycine was 
added to quench the reaction. Cells were centrifuged at 500g for 4 min at 4oC, 
cell pellet obtained and lysed with 500 µl lysis buffer [50mM sodium phosphate 
buffer (pH 8.0), 150mM NaCl, 1% Nonidet P-40, 0.5% Triton X-100, 1mM PMSF 
and protease inhibitor cocktail] followed by sonication on ice. The cell lysate was 
incubated with streptavidin-coated magnetic beads (0.5mg/50ul) overnight with 
end-over-end (360o) shaking at 4oC. Biotinylated proteins-streptavidin magnetic 
bead complex was isolated using magnetic stand (DynaMag-Spin, Invitrogen, 
Oslo, Norway). Supernatant was carefully removed and magnetic bead complex 
was washed with lysis buffer. The biotinylated proteins-streptavidin complex was 
dissociated with 40 µl Laemmeli buffer (125mM Tris-HCl pH 6.8, 4% SDS, 20% 
glycerol, 5% β-mercaptoethanol) by heating at 90-95oC for 10 min. After 
vortexing, magnetic beads were separated as above, and the supernatant (30µl) 
was used to determine AT1 receptor protein by Western blotting as mentioned 
above.  
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 Measurement of PKC activity 3.1.10.
 Cells were pre-treated with tempol (1mM) and AT1 receptor blocker candesartan 
(1µM), separately, for 10 min followed by treatment with DETC (500µM, 2 hr). 
DETC treatment in the absence of tempol and candesartan was also carried out 
separately. Control cells were treated with vehicle (DMSO). Thereafter, cells 
were treated with angiotensin II (1µM, 10 min). Cells were taken in lysis buffer 
(mM: 20 MOPS, 50 β-glycerolphosphate, 50 sodium fluoride, 1 sodium 
orthovanadate, 5 EGTA, 2 EDTA, 1% Triton-100X, 1 dithiothreitol, 1 PMSF and 
protease inhibitor cocktail) and passed 4-5 times through a 23-gauge needle.  
PKC activity in cell homogenate (10µg) was measured using ELISA-based assay 
kit (Enzo Life Sciences, Farmingdale, NY). 
3.2. Methods used in Animal studies 
 Animal procurement  3.2.1.
Male Sprague Dawley (SD) rats weighing 200-250gm were purchased from 
Harlan laboratories (Indianapolis, IN). The rats were housed in plastic cages in 
the University of Houston animal care facility. Rats were acclimatized for one 
week and used as per the National Institute of Health guidelines and approved 
protocols by Institutional Animal Care and Use Committee (IACUC). Animals 
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were provided with rodent chow and water ad libitum.  
 Animal treatments 3.2.2.
Animals were divided into four groups: Control group, DETC treated group, 
DETC + tempol treated group, and tempol treated group. DETC groups received 
intra-peritoneal (Phillips & Schmidt-Ott) injection of DETC (10mg/kg BW/daily) for 
two weeks. DETC was dissolved in saline and sterilized by filtering through 0.2 
µm filters each day.  Control and tempol groups were injected with sterilized 
saline. DETC plus tempol, and tempol groups of rats received tempol (2mM, 
Santa Cruz Biotechnology) in drinking water. Control and DETC groups of rats 
were given drinking water only (without tempol). Rats had had free access of rat 
chow and water supplemented with and without tempol. Tempol-supplemented 
water was changed daily to minimize its oxidation. Water and food intake were 
recorded every day.  
 Animal surgery  3.2.3.
Animals were first knocked-down with isoflurane and then anesthetized with 
Inactin (150µg/kg BW, IP). Under deep anesthesia tracheotomy was performed 
to facilitate spontaneous breathing. Right carotid artery was cannulated with 
pressure transducer to measure blood pressure using software PowerLab 
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(ADInstruments, Colorado Springs, CO). After measuring blood pressure, left 
jugular vein was catheterized with PE-50 tubing for saline and candesartan 
infusions.  A midline abdominal incision was made and urinary bladder was 
catheterized with PE-10 tubing to collect urine. Rats were infused with saline (1% 
BW ml/h) to prevent dehydration and to maintain stable urinary output.	  
 Blood pressure measurement 3.2.4.
Blood pressure was measured in anaesthetized rats. After cannulating right 
carotid artery, blood pressure was recorded for 30 minutes using PowerLab 
software (ADInstruments, Colorado Springs, CO). A stable blood pressure from 
this recording was chosen and reported.  
	  	  
	  
	  
	  
	  
54	  	  
	  
	  
	  
	  
Figure 5. Protocol for renal function studies.  
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 Urine and blood collection 3.2.5.
Two urine samples (C1 and C2, each 30 min period) from cannulated bladder 
were collected during saline infusion. Thereafter, a bolus dose of candesartan in 
saline (10 µg/kg bw, IV) was given and four urine samples (D1, D2, D3 and D4, 
each for 30 min period) were collected. Blood samples were collected through 
heart with 1 ml syringe. Blood samples were centrifuged at 2,000g for 10 min at 4 
oC and blood plasma obtained. Urine and blood plasma samples were stored at -
80 oC for further analyses. Urine and plasma samples were used to measure 
creatinine and sodium.  
 Measurement of sodium and creatinine in urine and plasma 3.2.6.
Sodium concentration in urine and plasma was measured using AAnalyst 400 
Atomic Absorption Spectrometer [(AAS), Perkin Elmer, Waltham, MA]. Creatinine 
concentration in urine and plasma was measured using a creatinine assay kit 
(BioVision, Cat # K625) to determine glomerular filtration rate (GFR). Natriuretic 
and diuretic responses to AT1 receptor blocker candesartan are represented as 
urinary sodium excretion (UNaV) and urine flow (µL/min), respectively in the result 
section. Creatinine clearance (CLclearance) was determined as an index of GFR. 
 UNaV, and urine flow were calculated using the following formulae: 
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 Removal of the kidneys and separation of superficial cortex 3.2.7.
Another set of male Sprague Dawley (SD) rats (weighing 200-250gm) was 
purchased from Harlan laboratories (Indianapolis, IN). These rats were 
maintained and drug treatments carried out as mentioned above. Thereafter, rats 
were knockdown with isoflurane and anesthetized with inactin (150µg/kg BW, 
i.p.). A midline abdominal incision was made with a sharp scissor; kidneys were 
removed and placed in KH buffer (pH 7.5). The kidneys were sliced coronally and 
superficial cortical tissues (rich in proximal tubules) were obtained using razor 
blade.   
 ROS measurement   3.2.8.
Renal tissues (100mg) were homogenized in tissue lysis buffer using Shredder 
SG3 (Pressure Biosciences Inc., South Easton, MA) and homogenates obtained. 
Homogenate samples (30µg proteins) were loaded in triplicates in a 96-well 
transparent plate. Superoxide probe dihydroethidium (DHE, 20µM, Life 
UNaV	  (μmol/min)	  =	  UF	  (µL/min)	  X	  Urinary	  sodium	  concentration	  (μmol/µL)	  
Urine	   flow	   [(UF)	   (µL/min)]	   =	   Urine	   volume	   (UV)/30	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technologies, Eugene, Oregon, USA) was mixed well in Krebs-Henseleit (KH, pH 
7.4) buffer, added in each well (final volume 200µl), and incubated for 30 min at 
room temperature. The plate was shaken for 5 min and DHE fluorescence signal 
measured using excitation (490 nm) and emission (610 nm) wavelengths in a 
spectrofluorometer (Varioskan, Thermo Scientific, Rockford, IL, USA).   
To measure H2O2 levels, samples (30µg proteins) were loaded in 
triplicates in a 96 well transparent plate. Thereafter, H2O2 probe dichloro-dihydro-
fluorescein diacetate (DCFHDA, 10µM, Life technologies, Eugene, Oregon, USA) 
was added and mixed well in KH buffer. After that, 200µl KH buffer containing 
DCFHDA was added in each well and incubated for 30 min at RT. DCFH 
fluorescence signal was measured using excitation (490nm) and emission 
(520nm) wavelengths in a spectrofluorometer (Varioskan, Thermo Scientific, 
Rockford, IL, USA).  
 Immunoprecipitation (IP) of nuclear Sp3 protein 3.2.9.
Kidney superficial cortex was homogenized and used to separate the nuclear 
extract using a commercial kit following manufacturer’s instructions (NE-PER kit, 
ThermoFisher scientific, Rockford, IL USA). Nuclear samples (250 µg protein, 
total volume 400 µl)  were mixed with 10µg Sp3 antibody (Santa Cruz 
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Biotechnology, Dallas, USA) followed by 2 h end-to-end shaking at 4 oC. 
Subsequently, 90µl sepharose A/G (Santa Cruz Biotechnology) was washed in 1 
ml IP buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1 mM DTT, 1 mM PMSF, 1% Triton X 100, 1X protease inhibitor cocktail] and 
centrifuged (14,000 rpm, 20 sec) and Sp3 antibody complex was added into it 
and incubated at end-to-end shaker overnight 4 oC. Next day, whole complex 
was washed with IP buffer and tris-HCL separately by centrifuging (14,000 rpm, 1 
min) at 4 oC. Laemmli buffer (60µl) was added in obtained pelleted beads and 
heated for 1 h at 37 oC followed by vortexing and centrifuging again as 
previously. Supernatant was collected; bromophenol blue dye (5 µl) was added 
and used for Western blotting.  
 Statistical analysis   3.2.10.
Data are presented as means ± SE. One-way ANOVA followed by Newman-
Keul’s post hoc test was used to compare the differences among the groups. 
Two-way ANOVA was employed for multiple group comparisons. Student’s t-test 
was used wherever appropriate. The P value of less than 0.05 was considered 
statistically significant. GraphPad prism software (GraphPad software ver. 5, San 
Diego, CA) was used to analyze the data.   
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3.3. Materials 
A 2.3 Kb Sp3 construct cloned into pCMV vector was a generous gift from Dr. 
Douglas A. Weigent, University of Alabama, Birmingham, AL. The sources of all 
other materials and chemicals purchased are written in parenthesis. Cell toxicity 
assay kit Cell Titer 96® Aqueous One Solution Assay, and PKC activity assay 
kits, (Promega, Madison, WI); Dihydroethidium, and dichloro-dihydro-fluorescein 
diacetate (Life technologies, Eugene, Oregon); Immobilon P memebrane 
(Millipore, Temecula, CA); FuGENE®6 transfection reagent, and protease 
inhibitor cocktail (Roche, Indianapolis, CA); Nuclear and cytosolic extraction kit 
(Pierce, Rockford, IL); cDNA Advantage-RT-for-PCR kit (Clontech Laboratories, 
Mountain View, CA); immunofluorescence-glass chambered slides, AT1R siRNA 
catalog # 4392420, Lipofectamine RNAiMAX transfection reagent, EZ-LINK 
Sulfo-NHS-SSbiotin, streptavidin magnetic beads, protein measuring BCA kit 
(ThermoFisher scientific, Rockford, IL); DMEM/F12, fetal bovine serum (FBS), 
epidermal growth factor (EGF), bovine pituitary hormone (BPE), and anti-biotic 
mixture (Invitrogen, Waltham, MA); Tempol, diethyldithiocarbamate (DETC), 
chemiluminescent reagent, (Santa Cruz Biotechnology, Dallas, Texas); Allstar 
control siRNA, and RNA extraction Qiagen mini kit (Qiagen, Valencia, CA); 
TaqMan human-specific primers for AT1 receptor (ID#Hs00258938-m1), and 18S 
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ribosome internal control (ID# Hs99999901-s1) (Life Technologies, Grand Island, 
NY); magnetic stand-DynaMag-Spin (Invitrogen, Oslo, Norway); Candesartan 
(gift from AstraZeneca, Cheshire, UK); Ang II (Sigma Aldrich, St. Louis, MO); 
PKC assay kit (Enzo Life Sciences, Farmingdale, NY). 
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4. RESULTS 
 Results section is sub-divided in (4.1.) Results from cell culture studies; 
and (4.2.) Results from animal studies. 
4.1. RESULTS FROM CELL CULTURE STUDIES 
 Toxicity measurement  4.1.1.
To determine whether the treatments of DETC, H2O2, and tempol affect 
cells viability, cell toxicity assay was performed. Viable cell number did not 
decrease and hence toxicity did not increase with DETC, tempol or H2O2 
treatment in HK2 cells (Fig. 6). 
 Dihydroethidium (DHE) probe detects superoxide radicals in a cell 4.1.2.
free system 
4.1.2.1 Effect of superoxide producing system xanthine/ xanthine oxidase on 
DHE fluorescence levels 
           To determine if DHE dye specifically detects superoxide, a cell free 
system that generates superoxide was employed. Xanthine and xanthine oxidase 
(XO) that produce superoxide radicals were added in KH buffer, which contains 
DHE probe. DHE fluorescence intensity increased 2-fold in xanthine/xanthine 
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oxidase than in controls (Fig. 7) Moreover, addition of DHE in KH buffer, which 
contains H2O2, did not show any significant increase in DHE fluorescence (Fig. 
7). This study clearly shows that DHE probe specifically detects superoxide but 
not H2O2.  
 Diethyldithiocarbamate [(DETC) an SOD inhibitor] treatment increases 4.1.3.
superoxide levels in HK2 cells 
4.1.3.1 Effects of SOD-inhibitor DETC and H2O2 on the levels of DHE 
fluorescence  
The following experiments were conducted to determine whether DETC, 
an SOD inhibitor, generates superoxide in HK2 cells. To achieve this, HK2 cells 
were treated with DETC in the presence and absence of tempol. DETC treatment 
significantly increased DHE fluorescence levels compared to vehicle treated cells 
(Fig. 3). However, H2O2 treatment did not have any significant effect on DHE 
fluorescence, suggesting that DHE specifically detects superoxide in a cell 
system (Fig. 8). In addition, this study also showed that H2O2 is not converted to 
superoxide by HK2 cells (Fig. 8). Pretreatment of cells with tempol (SOD-
mimetic) abolished DETC-mediated increase in DHE fluorescence levels, 
suggesting that DETC produces superoxide and tempol is a potent antioxidant 
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that specifically scavenges superoxide (Fig. 8).  
4.1.3.2 Effects of H2O2, 3-AT and SOD-inhibitor DETC on the levels of DCFHDA 
fluorescence 
 To determine exogenously added and endogenously produced H2O2 
levels, DCFHDA fluorescent probe was used.  DCFHDA is a non-fluorescent 
molecule, which is converted into DCF by intracellular esterases. Upon oxidation 
by ROS, such as H2O2 it fluoresces. Treatment of cells with either exogenous 
H2O2 or catalase inhibitor 3-AT, that produces endogenous H2O2, significantly 
increased DCF fluorescence levels compared to vehicle treated cells (Fig. 9). 
These results suggest that H2O2 when added exogenously as well as produced 
endogenously increased intracellular levels of H2O2. DETC treatment, that 
produces superoxide, did not have any effect on DCF fluorescence (Fig. 9), 
suggesting that this probe specifically detect H2O2. 
 DETC treatment increases nuclear accumulation of Sp3 and NF-κB 4.1.4.
proteins in HK2 cells 
4.1.4.1 Effect of SOD-inhibitor DETC and H2O2 on nuclear accumulation of Sp3 
protein 
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           To determine if superoxide and H2O2 affect nuclear translocation of Sp3 
protein, HK2 cells were treated with DETC, H2O2 and vehicle. Western blotting 
showed the presence of three bands for Sp3 protein (115, 100 & 78 kDa) in the 
nuclear extract of HK2 cells (Fig. 10). Sp3 gene is expressed into three isoforms 
of Sp3 protein (Davie et al., 2008). Densitometric analysis of Sp3 protein bands 
showed that DETC treatment significantly increased nuclear levels of Sp3 
compared to vehicle treated cells. Pretreatment of the cells with tempol 
attenuated this effect. However, H2O2 did not show any significant effect on 
nuclear accumulation of Sp3 protein levels (Fig. 10). This experiment suggests 
that Sp3 is a redox-sensitive transcription factor, which can be activated by high 
levels of superoxide radicals.  
4.1.4.2 Effect of SOD-inhibitor DETC and H2O2 on nuclear accumulation of NF-
κB protein 
          To determine the effect of superoxide and H2O2 on NF-κB nuclear 
accumulation, Western blotting was conducted. Densitometric analysis of nuclear 
NF-κB protein bands showed that DETC treatment significantly increased nuclear 
levels of NF-κB compared to vehicle treated cells (Fig. 11). Pretreating the cells 
with tempol attenuated this effect (Fig. 11). However, H2O2 did not show any 
effect on nuclear accumulation of NF-κB protein (Fig. 11). These results suggest 
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that superoxide activates another redox-sensitive transcription factor NF-κB, 
which can be activated by high levels of superoxide radicals.  
 DETC treatment increases AT1 receptor mRNA, and protein 4.1.5.
expressions in HK2 cells  
4.1.5.1 Effects of SOD-inhibitor DETC and H2O2 on AT1 receptor mRNA 
expression  
 To demonstrate the effect of superoxide and H2O2 on gene expression of 
AT1 receptor, levels of AT1 receptor mRNA were measured by RT-qPCR. 
Results showed that DETC treatment significantly increased mRNA levels of AT1 
receptor compared to vehicle treated cells (Fig. 12). Pretreatment of cells with 
tempol attenuated this effect (Fig. 12). H2O2 treatment did not show any 
significant effect on the AT1 receptor mRNA levels (Fig. 12).  
4.1.5.2 Effect of SOD-inhibitor DETC on AT1 receptor protein levels 
To examine the effects of superoxide on the levels of AT1 receptor protein, 
Western blotting was conducted. Western blotting demonstrated a single 41-kDa 
protein band for AT1 receptor. Densitometric analyses of bands showed that 
DETC treatment significantly increased the levels of AT1 receptor protein 
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compared to controls (Fig. 13). This effect was attenuated by tempol treatment 
(Fig. 13).   
 Sp3 plasmid transfection increases Sp3 and AT1 receptor proteins in 4.1.6.
HK2 cell 
4.1.6.1 Effect of Sp3 transfection on the levels of Sp3 and AT1 receptor proteins 
To determine the effect of Sp3 plasmid on AT1 receptor protein levels, 
cells were transfected with Sp3 plasmid and empty vector. Western blot image 
showed the presence of three distinct bands of 115, 100, and 78-kDa for Sp3 
protein and a single band of 41-kDa for AT1 receptor. Densitometric analysis of 
the bands demonstrated that Sp3 plasmid transfection significantly increased the 
expression levels of Sp3 and AT1 receptor proteins compared to empty vector 
(Fig. 14A, B). 
 Sp3 siRNA transfection decreases Sp3 and AT1 receptor proteins in 4.1.7.
HK2 cells 
4.1.7.1 Effect of Sp3 siRNA on the expressions of Sp3 and AT1 receptor 
proteins levels 
To confirm that Sp3 regulates AT1 receptor protein expression, HK2 cells 
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were transfected with Sp3 siRNA and all-star negative control siRNA. Sp3 siRNA 
transfection significantly reduced the expression levels of AT1 receptor protein 
compared to all-star negative control siRNA treated cells. Densitometric analysis 
of the bands showed that Sp3 siRNA transfection significantly attenuated the 
expression levels of Sp3 and AT1 receptor proteins compared to all-star negative 
control siRNA treated cells (Fig. 15A, B).   
 Sp3 siRNA decreases AT1 receptor protein expression in the 4.1.8.
presence of DETC in HK2 cells 
4.1.8.1 Effect of Sp3 siRNA on AT1 receptor protein expression in the presence 
of SOD-inhibitor DETC 
To confirm whether superoxide mediated up-regulation of renal AT1 
receptor protein and function is mediated via Sp3 transcription factor, cells were 
transfected with Sp3 and control siRNA in the presence DETC, and AT1 receptor 
protein was measured.  Western blotting results showed a single band of 41-kDa 
for AT1 receptor. Densitometric analysis of the bands showed that Sp3 siRNA 
decreased AT1 receptor protein expression in the presence of DETC compared 
to control siRNA treated cells (Fig. 16). DETC alone increased AT1 receptor 
protein expression compared to control siRNA treated cells (Fig. 16). This 
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experiment confirms that basal AT1 receptor protein expression is regulated by 
Sp3 transcription factor. Additionally, this experiment also demonstrates that 
superoxide (DETC-induced) via Sp3 transcription factor up-regulates renal AT1 
receptor protein expression.  
 DETC treatment increases membranous AT1 receptor protein and 4.1.9.
function in HK2 cells 
4.1.9.1 Effect of SOD-inhibitor DETC on cell surface AT1 receptor protein levels  
To determine if superoxide affects the levels of membranous AT1 receptor levels, 
HK2 cells were treated with DETC followed by the detection of cell surface AT1 
receptors by i) immunofluorescence imaging and ii) performing Western blot of 
the biotinylated cross-linked cell surface proteins.  
i) Immunofluorescence imaging of AT1 receptor protein expression: 
DETC treatment increased membranous AT1 receptor protein 
expression in impermeabilized cells as detected by 
immunofluorescence technique (Fig. 17b). This effect was attenuated 
by tempol treatment (Fig. 17c). 
ii) Western blotting the biotinylated cross-linked cell surface 
proteins: Membranous protein isolated with biotin-streptavidin 
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approach used for Western blotting.  Densitometric analysis of the 
bands showed that DETC treatment significantly increases 
membranous AT1 receptor protein levels compared to control cells 
(Fig. 18). Western blot image showed the presence of a single 41-kDa 
band for AT1 receptor protein. This effect was attenuated by tempol 
treatment (Fig. 18). Biotin-streptavidin approach corroborated 
immunofluorescence-imaging results. 
4.1.9.2 Effect of SOD-inhibitor DETC on PKC (AT1 receptor function) activity 
Activation of AT1 receptor in response to Ang II results in the activation of 
downstream signaling molecules including PKC. Therefore, PKC activity has 
been used as an indirect measurement of AT1 receptor function. AT1 receptor 
ligand angiotensin II (1µM) treatment increased PKC activity in naïve cells 
(absence of DETC) compared to control naive cells (Fig. 19). Angiotensin II 
further increased PKC activity in DETC-treated cells. The effect of angiotensin II 
on PKC was attenuated by AT1 receptor blocker candesartan and SOD-mimetic 
tempol in DETC treated cells (Fig. 19). This experiment demonstrates that 
superoxide mediated up-regulation of AT1 receptor protein expression is 
translated to higher renal AT1 receptor function. 
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 NF-κB p-65 plasmid transfection increases NF-κB protein but not AT1 4.1.10.
receptor in HK2 cells 
4.1.10.1 Effect of NF-κB p-65 vector on the levels of NF-κB and AT1 
receptor proteins 
To determine the effect of NF-κB p-65 vector on AT1 receptor protein levels, HK2 
cells were transfected with NF-κB p-65 and empty vectors. Western blot images 
showed the presence of a single 65-kDa and 41-kDa band for NF-κB p-65 and 
AT1 receptor respectively. Densitometric analysis of the bands showed that NF-
κB p-65 vector transfection significantly increased the expression levels of NF-κB 
p-65 protein (20A) but did not have any significant effect on AT1 receptor protein 
compared to empty vector treated HK2 cells (Fig. 20B).  
 NF-κB p-65 shRNA transfection and PDTC decreases NF-κB protein 4.1.11.
levels but overexpress AT1 receptor mRNA in HK2 cells 
4.1.11.1 Effect of NF-κB p-65 shRNA on the levels of NF-κB protein and 
AT1 receptor mRNA 
To confirm the role of NF-κB in the regulation of AT1 receptor expression, if any, 
HK2 cells were treated with NF-κB and control shRNAs and the levels of NF-κB 
	  	  
	  
	  
	  
	  
71	  	  
	  
	  
	  
protein and AT1 receptor mRNA expression were measured by western blotting 
and RT-qPCR, respectively. Densitometric analyses of protein bands showed 
that NF-κB shRNA decreased NF-κB protein levels compared to control shRNA 
treated cells. RT-qPCR results revealed that NF-κB shRNA significantly 
increased the expression levels of AT1 receptor mRNA compared to control 
shRNA treated cells (Fig 21A). This experiment suggests that NF-κB transcription 
factor has an inhibitory effect on AT1 receptor mRNA expression in HK2 cells. 
4.1.11.2 Effect of PDTC on AT1 receptor mRNA expression 
Similar experiment was designed to confirm an inhibitory effect of NF-κB on AT1 
receptor mRNA expression. In this experiment, HK2 cells were treated with 
PDTC (an NF-κB inhibitor). RT-qPCR data analysis showed that PDTC 
significantly increased the expression levels of AT1 receptor mRNA compared to 
vehicle treated cells (21B). This experiment again corroborates that NF-κB 
transcription factor has an inhibitory effect on AT1 receptor mRNA expression in 
HK2 cells. 
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4.2. RESULTS FROM ANIMAL STUDIES 
 DETC treatment did not have any significant effect on body weight, 4.2.1.
food and water intake in Sprague Dawley (SD) rats 
4.2.1.1 Effect of SOD-inhibitor DETC on body weight, food and water intake 
DETC treatment with and without tempol did not show any significant effect on 
body weight, food, and water intake compared to control groups of rats (Fig 
22A,B,C). Tempol-alone treatment also did not show any significant effect on 
these parameters (Fig 22A,B,C).    
 DETC treatment increases blood pressure in SD rats 4.2.2.
4.2.2.1 Effect of SOD-inhibitor DETC on blood pressure 
DETC treatment in rats significantly increased systolic and diastolic blood 
pressures compared to control group of rats (Fig. 23). DETC-induced increase in 
blood pressure was reduced in tempol treated rats. Tempol treatment alone did 
not significantly affect blood pressure in rats (Fig. 23).  
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 DETC treatment increases superoxide levels in kidney superficial 4.2.3.
cortex of SD rats 
4.2.3.1 Effect of SOD-inhibitor DETC on DHE and DCFHDA fluorescence 
Kidney superficial cortex, rich in proximal tubules, from the rats treated with 
DETC showed higher levels of superoxide compared to control groups (Fig. 24), 
which decreased in rats treated with tempol (Fig. 24). Rats treated with tempol-
only did not show any significant difference in superoxide levels compared to 
control rats. The levels of H2O2 measured as DCFHDA fluorescence did not 
change in kidney cortex from these rats (Fig. 25).   
 DETC treatment causes greater magnitude of diuresis and natriuresis 4.2.4.
in response to candesartan in SD rats 
4.2.4.1 Effect of SOD-inhibitor DETC on diuresis and natriuresis 
There were significantly greater increases in diuresis and natriuresis in response 
to AT1 receptor antagonist candesartan in DETC treated compared to control 
rats (Fig. 26, 27), which reduced in tempol treated rats (Fig. 26, 27). This 
experiment demonstrated that superoxide (DETC-induced) increases AT1 
receptor function in SD rats because i) blocking AT1 receptor with candesartan 
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increases excretion of sodium (natriuresis) and water (diuresis), and ii) tempol 
treatment in response to candesartan exhibits reduced natriuresis and diuresis in 
DETC treated rats. However, there was no effect in response to candesartan on 
diuresis and natriuresis in rats treated with tempol alone (Fig. 26, 27). 
 DETC treatment causes increased acetylation of lysine of Sp3 protein 4.2.5.
in SD rats 
4.2.5.1 Effect of SOD-inhibitor DETC on acetylation of lysine of Sp3 protein 
To investigate whether acetylation is one of the causes of nuclear translocation 
of Sp3, immunoprecipitation-Western blotting (IP-WB) experiments were 
performed in the nuclear extracts of KSC of SD rats. Nuclear extracts from DETC 
rats showed increased pan-acetylation of lysine of Sp3 protein compared to 
control or tempol-only treated rats (Fig. 28A). Importantly, tempol treatment 
significantly attenuated this effect compared to DETC treated rats (Fig. 28A). 
There was no effect in response to candesartan on diuresis and natriuresis in 
rats treated with tempol alone (Fig. 28A). These results demonstrate that 
acetylation of lysine could be one of the mechanisms of Sp3 protein nuclear 
accumulation/translocation in DETC treated rats. 
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 DETC treatment did not have any effect on Sp3 protein 4.2.6.
phosphorylation in SD rats 
4.2.6.1 Effect of SOD-inhibitor DETC on Sp3 protein phosphorylation 
To investigate the role of phosphorylation in nuclear accumulation/translocation 
of Sp3, immunoprecipitation-Western blotting experiments were performed in the 
nuclear extracts of KSC of SD rats. Nuclear extracts from DETC rats did not 
show any significant increment in phosphorylation of Sp3 protein compared to 
control or tempol-only treated rats (Fig 28B). Importantly, tempol treatment 
significantly attenuated this effect compared to DETC treated rats (Fig 28B). 
There was no effect in response to candesartan on diuresis and natriuresis in 
rats treated with tempol alone (Fig. 28B). These results demonstrate that 
phosphorylation of Sp3 protein is not involved in nuclear translocation of Sp3 in 
DETC treated rats. 
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Figure 6. SOD-inhibitor DETC, H2O2 and tempol do not cause toxicity in 
HK2 cells. 
Cells were treated with DETC (500µΜ, 2 h), H2O2 (50µΜ, 30 min), and tempol 
(1mM, 2 h). Cells were pre-treated with tempol for 10 min before adding DETC. 
DETC = Diethyldithiocarbamate, T = Tempol, D = DETC, H2O2 = Hydrogen 
peroxide. Commercial kit as described in Methods was used to detect cell 
toxicity. Absorbance at 490 nm is plotted as bar graph. Bars represent results as 
mean ± SEM, P<0.05. *significantly different from control, #significantly different 
from DETC. Data were analyzed by one-way ANAOVA followed by post hoc 
Newman-Keuls analysis. N = 3 separate experiments. 
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Figure 7. Superoxide producing system xanthine/xanthine oxidase 
increases DHE fluorescence levels in cell-free system. 
Xanthine and XO were dissolved in KH buffer containing DHE probe (25 µM) and 
fluorescence was measured by spectrofluorometer using excitation 490 and 
emission 610 nm wavelengths. (Detail in methods). X = Xanthine, XO = Xanthine 
oxidase, DHE = Dihydroethidium, H2O2 = Hydrogen peroxide. Bars represent 
results as mean ± SEM. P<0.05, *significantly different from X+DHE. Data were 
analyzed by one-way ANAOVA followed by post hoc Newman-Keuls analysis. N 
= 3 separate experiments. 
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Figure 8. SOD- inhibitor DETC increases DHE fluorescence (superoxide 
levels) in HK2 cells. 
Cells were loaded with DHE probe followed by treatment with SOD- inhibitor 
DETC in the absence and presence of tempol, and H2O2 and DHE fluorescence 
levels were measured. (Drug treatments and DHE measurement are described in 
Methods). DETC = Diethyldithiocarbamate, T = Tempol, D = DETC, H2O2 = 
Hydrogen peroxide, DHE = Dihydroethidium. Bars represent results as mean ± 
SEM, P<0.05. *significantly different from control, #significantly different from 
DETC. Data were analyzed by one-way ANAOVA followed by post hoc Newman-
Keuls analysis. N = 5 separate experiments. 
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Figure 9. SOD- inhibitor DETC does not increase DCFH fluorescence in HK2 
cells. 
Cells were loaded with DCFHDA probe followed by treatment with H2O2, catalase 
inhibitor 3-AT, and DETC, and DCFH fluorescence levels were measured (Drug 
treatments, and DCFHDA measurements are described in Methods). DETC = 
Diethyldithiocarbamate, T = Tempol, D = DETC, H2O2 = Hydrogen peroxide, 
DCFHDA = Dichloro-dihydro-fluorescein diacetate, 3-AT = 3-Amino-1,2,4-
triazole. Bars represent results as mean ± SEM, P<0.05. Data were analyzed by 
one way ANAOVA followed by post hoc Newman-Keuls analysis. *Significantly 
different from control, #significantly different from control. N = 5 separate 
experiments. 
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Figure 10. SOD- inhibitor DETC increases nuclear levels of Sp3 protein in 
HK2 cells. 
Cells were treated with DETC, and H2O2 in the absence and presence of tempol, 
nuclear proteins isolated and Sp3 levels determined by Western blotting (Details 
in methods). Upper panel: representative blot of Sp3 (top) and nuclear protein 
loading control histone 3 (bottom). Lower panel: bars represent ratios of the 
densities of Sp3 and histone 3 proteins bands. Both Sp3 protein bands were 
considered for quantification. DETC = Diethyldithiocarbamate, T = Tempol, D = 
DETC, H2O2 = Hydrogen peroxide. Results are mean ± SEM. P<0.05, 
*significantly different from control, #significantly different from DETC. Data were 
analyzed by one-way ANAOVA followed by post hoc Newman-Keuls analysis. N 
= 5 separate experiments. 
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Figure 11. SOD- inhibitor DETC increases nuclear levels of NF-κB 
accumulation in HK2 cells. 
Cells were treated with DETC, and H2O2 in the absence and presence of tempol, 
nuclear proteins isolated and NF-κB levels determined by Western blotting 
(Details in methods). Upper panel: representative blot of NF-κB (top) and nuclear 
protein loading control lamin B (bottom). Lower panel: bars represent ratios of the 
densities of NF-κB and histone 3 proteins bands. DETC = 
Diethyldithiocarbamate, T = Tempol, D = DETC, H2O2 = Hydrogen peroxide. 
Results are mean ± SEM. P<0.05, *significantly different from control, 
#significantly different from DETC. Data were analyzed by one-way ANAOVA 
followed by post hoc Newman-Keuls analysis. N = 4 separate experiments. 
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Figure 12. SOD- inhibitor DETC increases AT1 receptor mRNA expression 
in HK2 cells. 
Cells were treated with DETC and H2O2 in the absence and presence of tempol 
and AT1 receptor mRNA was determined by RT-qPCR (Details in methods). 
Reference gene 18S was used to normalize the data. DETC = 
Diethyldithiocarbamate, T = Tempol, D = DETC, H2O2 = Hydrogen peroxide. Bars 
represent results as mean ± SEM. P<0.0.05, *significantly different from control, 
#significantly different from DETC. Data were analyzed by one-way ANAOVA 
followed by post hoc Newman-Keuls analysis. N = 4 separate experiments. 
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Figure 13. SOD- inhibitor DETC increases AT1 receptor protein levels in 
HK2 cells. 
Cells were treated with DETC in the absence and presence of tempol and cell 
lysate was used to measure AT1 receptor protein by Western blotting (Details in 
methods). Upper panel: representative blot of AT1 receptor (top) and loading 
control GAPDH (bottom).  Lower panel: bars represent ratios of the densities of 
AT1 receptor and GAPDH proteins bands. DETC = Diethyldithiocarbamate, T = 
Tempol, D = DETC. Results are mean ± SEM. P<0.05, *significantly different 
from control, #significantly different from DETC. Data were analyzed by one-way 
ANAOVA followed by post hoc Newman-Keuls analysis.  N = 4 separate 
experiments. 
	  
	  	  
	  
	  
	  
	  
84	  	  
	  
	  
	  
Control Sp3
0.0
0.1
0.2
0.3
0.4
0.5
*
115 kDa
100 kDa
GAPDH 38 KDa
Sp3 isoforms
Sp
3/
G
AP
D
H
 (D
en
si
ty
)
(A)
Control Sp3
0.0
0.1
0.2
0.3
0.4
0.5
*
   AT1R
GAPDH
A
T
1R
/G
A
P
D
H
 (
D
en
si
ty
)
(B)
	  
Figure 14. Sp3 overexpression increases AT1 receptor protein expression 
in HK2 cells.  
HK2 cells were transfected with Sp3 plasmid and cell lysate was used to 
measure Sp3 (A) and AT1 receptor (B) proteins by Western blotting (Details in 
methods). Upper panels: representative blots of Sp3 (A), AT1 receptor (B) and 
protein loading controls GAPDH (A, B).  Lower panels: bars represent ratios of 
the densities between Sp3 and GAPDH (A) and AT1 receptor and GAPDH (B). 
Both the Sp3 protein bands were considered for quantification (A). Results are 
mean ± SEM, P<0.05. Data were analyzed by Student’s t-test.  *Significantly 
different from control. N = 4 separate experiments.  
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Figure 15. Sp3 siRNA decreases AT1 receptor protein expression in HK2 
cells. 
HK2 cells were transfected with Sp3 and control siRNAs and cell lysate was used 
to measure protein levels of Sp3 (A) and AT1 receptor (B) by Western blot (Details 
in methods). Upper panels: representative blots of Sp3 (A), AT1 receptor (B) and 
protein loading control GAPDH (A, B).  Lower panels: bars represent ratios of the 
densities between Sp3 and GAPDH (A) and AT1 receptor and GAPDH (B). Both 
the Sp3 protein bands were considered for quantification (A). Results are mean ± 
SEM, P<0.05. Data were analyzed by Student’s t-test. *significantly different from 
control. N = 3-5 separate experiments. 
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Figure 16. Sp3 siRNA in the presence of SOD- inhibitor DETC decreases 
AT1 receptor protein expression in HK2 cells. 
Cells were transfected with Sp3 and control siRNAs (100ng, 24 h) followed by 
DETC treatment (500µM, 2 h) and cells lysate was used to measure protein 
levels of AT1 receptor and Sp3 (data not shown) by Western blotting. Upper 
panel: representative blot of AT1 receptor and loading control GAPDH.  Lower 
panel: bars represent ratios of the densities of AT1 receptor and GAPDH proteins 
bands. DETC = Diethyldithiocarbamate. Results are mean ± SEM. P<0.05, 
*significantly different from control, #significantly different from DETC, N = 3 
separate experiments. 
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Figure 17. SOD- inhibitor DETC increases cell surface AT1 receptor levels in HK2 
cells.  
Cells were treated with vehicle (control) and DETC in the absence and presence of 
tempol (Details in the methods). Cells were fixed with formalin followed by labeling with 
primary AT1 receptor and secondary Alexa488 conjugated antibodies. Cells were 
mounted with media containing nuclear dye DAPI. The AT1 receptor antibody used 
recognizes extracellular loop of the receptor. Arrows in panel b show cell surface AT1 
receptor (green). Nuclei are blue stained with DAPI (panels: a, b and c). DETC = 
Diethyldithiocarbamate, N = 4 separate experiments. 
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Figure 18. SOD- inhibitor DETC increases cell surface AT1 receptor levels 
in protein in HK2 cells. 
Cell surface proteins were biotinylated and isolated with streptavidin-
conjugated magnetic beads followed by measuring AT1 receptor proteins by 
Western blotting (details in methods). Upper panel: representative blot of AT1 
receptor.  Lower panel: bars represent the densities of AT1 receptor protein 
bands. DETC = Diethyldithiocarbamate, T = Tempol, D = DETC. Results are 
mean ± SEM. P<0.05, Data were analyzed by one-way ANAOVA followed by 
post hoc Newman-Keuls analysis. *significantly different from control, 
#significantly different from DETC. N = 5 separate experiments. 
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Figure 19. SOD- inhibitor DETC increases angiotensin II mediated PKC 
activity in HK2 cells. 
 Cells were treated with vehicle and DETC in the absence and presence of 
candesartan (Cand), and tempol. Thereafter, cells were treated with or without 
angiotensin II (Ang II), lysates obtained and used to measure PKC activity 
(Details in methods). Ang II = Angiotensin II, Cand = Candesartan, DETC = 
Diethyldithiocarbamate, T = Tempol, D = DETC. Bars represent results as mean 
± SEM. Data were analyzed by one-way ANAOVA followed by post hoc 
Newman-Keuls analysis. P<0.05, *significantly different from control, 
#significantly different from Ang II, $significantly different from DETC+Ang II. N = 
3-6 separate experiments. 
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Figure 20. NF-κB p-65 overexpression does not increase AT1 receptor 
protein expression in HK2 cells. 
HK2 cells were transfected with NF-κB p-65 plasmid and cell lysate was used to 
measure NF-κB (A) and AT1 receptor (B) proteins measured by Western blotting 
(Details in methods). Upper panels: representative blots of NF-κB (A), AT1 
receptor (B) and protein loading controls GAPDH (A, B).  Lower panels: bars 
represent ratios of the densities between NF-κB and GAPDH (A) and AT1 
receptor and GAPDH (B). Results are mean ± SEM. P<0.05, Data were analyzed 
by Student’s t-test. *significantly different from control. N = 3 separate 
experiments. 
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Figure 21. NF-κB shRNA PDTC increases AT1 receptor mRNA expression in 
HK2 cells.  
Cells were treated with PDTC [(a) an NF-κB inhibitor] and NF-κB shRNA (b) and 
AT1 receptor mRNA was determined by RT-qPCR (Details in methods). 
Reference gene 18S was used to normalize the data. PDTC = 
Pyrrolidinedithiocarbamate. Bars represent results as mean ± SEM. P<0.05, 
*significantly different from control, Data were analyzed by Student’s	  t-­‐test. N = 3-
4 separate experiments. 
(A) 
(B) 
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Figure 22. (A, B, C). SOD- inhibitor DETC with or without tempol does not 
affect body weight, food or water intake in SD rats. 
SD rats were treated with vehicle and DETC in the absence and presence of 
tempol, and body weight, food, and water intake were measured every alternate 
day. (Details in methods). DETC = Diethyldithiocarbamate. Results as mean ± 
SEM, P<0.05. Data were analyzed by one-way ANAOVA followed by Bonferroni 
post-test analysis. N = 10 rats in each group.  
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Figure 23. SOD- inhibitor DETC increases blood pressure in SD rats. 
SD rats were treated with vehicle and DETC in the absence and presence of 
tempol and blood pressure (systolic and diastolic) was measured in anesthetized 
rats. (Details in methods). DETC = Diethyldithiocarbamate. Bars represent 
results as mean ± SEM, P<0.05. Data were analyzed by two-way ANOVA 
followed by Bonferroni post-test analysis. *significantly different from control, 
#significantly different from DETC. N = 5-8 rats in each group.   
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Figure 24. SOD- inhibitor DETC increases DHE fluorescence in renal 
tissues of SD rats.  
SD rats were treated with vehicle and DETC in the absence and presence of 
tempol, tissue homogenate prepared and used to measure superoxide levels 
using DHE probe. (Details in methods). DETC = Diethyldithiocarbamate, DHE = 
Dihydroethidium. Bars represent results as mean ± SEM, P<0.05. Data were 
analyzed by one-way ANAOVA followed by post hoc Newman-Keuls analysis. 
*Significantly different from control, #significantly different from DETC, N = 4-6 
rats in each group. 
 
 
	  	  
	  
	  
	  
	  
96	  	  
	  
	  
	  
Control DETC Tempol+DETC Tempol
0
200
400
600
800
*
D
C
FH
D
A 
flu
or
es
ce
nc
e
	  
Figure 25. SOD- inhibitor DETC does not increase DCFH fluorescence in 
renal tissues of SD rats. 
SD rats were treated with vehicle and DETC in the absence and presence of 
tempol, tissue homogenate prepared and used to measure H2O2 levels using 
DCFHDA probe. (Details in methods). DETC = Diethyldithiocarbamate, H2O2 = 
Hydrogen peroxide, DCFHDA = Dichloro-dihydro-fluorescein diacetate. Bars 
represent results as mean ± SEM, P<0.05. Data were analyzed by one-way 
ANAOVA followed by post hoc Newman-Keuls analysis. *Significantly different 
from control,  N = 6 rats in each group. 
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Figure 26. SOD-inhibitor DETC increases urine flow (diuresis) in response 
to candesartan in SD rats.  
Urine flow in response to AT1 receptor antagonist candesartan (10 µg/kg iv; 
bolus) was determined in anesthetized rats. (Details in methods). V = average 
of two 30-min saline infusion periods. C = average of four 30-min drug 
(candesartan) infusion periods. DETC = Diethyldithiocarbamate. Bars 
represent results as mean ± SEM, P<0.05. Data were analyzed by two-way 
ANAOVA followed by Bonferroni post-test analysis. *Significantly different from 
V (vehicle), #significantly different from control C, $ significantly different from 
DETC C. N = 5-8 rats in each group 
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Figure 27. SOD-inhibitor DETC increases natriuresis (UNaV) in response to 
candesartan in SD rats. 
 Natriuresis or urinary sodium excretion (UNaV) in response to AT1 receptor 
antagonist candesartan (10 µg/kg iv bolus) was determined in anesthetized rats. 
(Details in methods). V = average of two 30-min period of saline infusion. C = 
average of four 30-min drug infusion after a bolus dose of candesartan was 
infused. DETC = Diethyldithiocarbamate. Bars represent results as mean ± SEM, 
P<0.05. Data were analyzed by two-way ANAOVA followed by Bonferroni post-
test analysis. *Significantly different from V (vehicle), #significantly different from 
control C, $ significantly different from DETC C, N = 5-8 rats in each group.   
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Figure 28. SOD- inhibitor DETC increases lysine acetylation and not 
phosphorylation of Sp3 in renal tissues of SD rats. 
 Nuclear extracts were prepared from renal tissues and used to 
immunoprecipitate Sp3 with Sp3 antibody.  Sp3 protein-antibody complexes 
were separated by SDS-PAGE and analyzed by Western blotting using anti-pan-
acetyl lysine (A) and anti-phosphorylated (B) antibodies (Details in methods). 
Subsequently, blots were stripped and re-probed with polyclonal anti-Sp3 
antibody. (A) Upper panels: representative blots of pan-acetyl lysine of Sp3 (left) 
and Sp3 protein ((right). Sp3 acetylated (left) and Sp3 protein (right) bands are 
indicated with arrows. (B) Upper panels: representative blots of phosphorylated 
Sp3 (left) and Sp3 protein (right). Phosphorylated Sp3 (left) and Sp3 protein 
bands are indicated with arrows. Lower panels (A, B): Quantification of 
acetylated-Sp3 (A) and phosphorylated-Sp3 (B). Bars are ratios between the 
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densities of acetylated-Sp3 and Sp3 protein (A), and phosphorylated-Sp3 and 
Sp3 proetin bands (B).  Results are mean ± SEM, P<0.05. Data were analyzed 
by one-way ANOVA followed by post hoc Newman-Keuls analysis. N = 3-4 rats.  
DETC = Diethyldithiocarbamate, T = Tempol, D = DETC. *Significantly different 
from control, #significantly different from DETC, N = 3-4 rats in each group.  
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Figure 29. RESULTS SUMMARY  
 
 
 
 
 
 
Superoxide 
-­‐98/-­‐79 
AT1 receptor mRNA 
X 
AT1 receptor protein 
High Blood pressure 
AT1 receptor Function 
Hydrogen peroxide 
 Sp3  Acetylation 
 Sp3  
	  	  
	  
	  
	  
	  
102	  	  
	  
	  
	  
5. DISCUSSION 
            Reactive oxygen species (ROS) burden (also known as oxidative stress) 
is known to increase renal AT1 receptor function that contributes to hypertension 
(Chugh et al., 2011, 2012; Montezano & Touyz, 2014; Nickenig & Harrison, 
2002). However, it is not known which of the ROS, namely superoxide or H2O2, 
mediates this effect. Especially there are contrasting reports regarding the role of 
H2O2 in hypertension (Y. Chen et al., 2007; Park et al., 2015; Schroder et al., 
2012). Further, AT1 receptor gene promoter possesses putative binding sites for 
redox-sensitive Sp3 and NF-κB transcription factors (TFs) (Cowling et al., 2005; 
Kambe et al., 2004), however, which one of them is involved in regulating renal 
AT1 receptor function is not known. Therefore, present studies were designed to 
examine roles and mechanisms of ROS (superoxide vs. H2O2) as well as TFs 
(Sp3 vs. NF-κB) in regulating renal AT1 receptor function. First, renal cells (HK2 
cells) were used to determine ROS and TFs specificity in regulation of AT1 
receptor function. Herein, we investigated the roles of superoxide and H2O2 in 
renal AT1 receptor mRNA and protein expressions and found that superoxide 
(DETC effect) but not H2O2 increases AT1 receptor mRNA and protein levels. 
Superoxide (DETC effect) also increased membranous abundance of AT1 
receptors. In addition, PKC activity was measured as an index of AT1 receptor 
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function. As indicated earlier that AT1 receptor promoter possesses binding sites 
for Sp3 and NF-κB, we elucidated their roles in AT1 receptor protein expression. 
For that, we transfected HK2 cells with Sp3 plasmid, and Sp3 siRNA separately 
and AT1 protein levels were measured. We found that increasing Sp3 protein 
levels increases while its depletion decreases AT1 receptor proteins in HK2 cells. 
Similar approach was employed to identify the role of NF-κB in the protein 
expression of AT1 receptor and found that NF-κB plasmid although increases its 
protein levels but fails to increase the levels of AT1 receptors. Taken together, 
studies in HK2 cells suggest that superoxide by involving Sp3 causes up-
regulation of renal AT1 receptor function. We further investigated the effect of 
superoxide radical on renal AT1 receptor function and blood pressure in Sprague 
Dawley (SD) rats. We also determined lysine-acetylation and serine-
phosphorylation of Sp3 in renal cortex as these have been linked in Sp3 
activation (Ehlting, Haussinger, & Bode, 2005; Pages, 2007).   
  To investigate the effects of ROS and their specificity (superoxide vs. 
H2O2) in the activation of transcription factors (Sp3 and NF-κB) and renal AT1 
receptor up-regulation, we used DETC (an SOD inhibitor) to increase superoxide 
levels in HK2 cells. SOD is a potent antioxidant enzyme, which scavenges 
superoxide radicals and contributes to maintain cellular redox homeostasis 
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(Valdivia, Perez-Alvarez, Aroca-Aguilar, Ikuta, & Jordan, 2009). DETC is an SOD 
inhibitor and previously has been used to increase superoxide levels in cell 
culture studies (A. D. Kim et al., 2014; Lapo et al., 2014). First, we confirmed the 
specificity of DHE probe for the detection of superoxide radical using xanthine 
and xanthine oxidase in a cell free system. Xanthine and xanthine oxidase 
system has previously been employed to generate superoxide radicals 
(Galbusera, Orth, Fedida, & Spector, 2006; Lacy, Gough, & Schmid-Schonbein, 
1998). Our results demonstrated that xanthine and xanthine oxidase significantly 
increased DHE fluorescence (Fig. 7). Moreover, we treated HK2 cells with DETC, 
and H2O2 and measured superoxide levels with DHE probe. Our results showed 
that DETC significantly increased superoxide levels in HK2 cells compared to 
control (Fig. 8). Importantly, tempol treatment significantly reduced the levels of 
superoxide in DETC treated cells (Fig. 8), suggesting that tempol efficiently 
scavenges superoxide. Tempol is a known antioxidant with SOD mimetic 
properties, which has extensively been used to scavenge superoxide in cells 
culture as well as in hypertensive animal models (Tawa, Shimosato, Iwasaki, 
Imamura, & Okamura, 2015; Wilcox, 2010). Enrique Cadenas and others have 
suggested that H2O2 might convert into superoxide, which can potentially 
increase superoxide levels. H2O2 treatment of HK2 cells did not increase DHE 
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fluorescence levels (Fig. 8) suggesting that H2O2 does not get converted into 
superoxide in HK2 cells and DHE is a specific probe for superoxide detection. 
Further, to determine cellular levels of H2O2, DCFHDA probe was used. DCFHDA 
is taken up by cells and is converted to DCFH by diesterases, which then gives 
fluorescence. Since there is controversy regarding DFCHDA as specific probe for 
H2O2 (L. E. George et al., 2012; Gough & Cotter, 2011; Lasagni Vitar et al., 2015; 
Taguchi, Ogura, Takanashi, Hashizoe, & Honda, 1996; Takanashi, Ogura, 
Taguchi, Hashizoe, & Honda, 1997), HK2 cells were treated with H2O2, 3-AT 
catalase inhibitor that increases endogenous H2O2 levels, and DETC separately. 
We found that cells treated with H2O2, and 3-AT showed increased DCFH 
fluorescence compared to control (Fig. 9). However, DETC treatment did not 
increase DCFH fluorescence, suggesting DCFHDA is a specific probe for H2O2 
(Fig. 9).   
         Many studies have demonstrated that ROS (termed oxidative stress) 
regulate a myriad of genes by modulating the activity of various redox-sensitive 
transcription factors such as nuclear factor kappa B p-65 (NF-κB), Sp3, NRF2, 
and activator protein (AP)-1 (Banday & Lokhandwala, 2015; Bhatt et al., 2014; 
Lavrovsky, Chatterjee, Clark, & Roy, 2000). However, specificity of ROS 
(superoxide vs. H2O2) in their activation has never been addressed. Our results 
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demonstrated that superoxide (DETC effect) but not H2O2 increased the nuclear 
accumulation of Sp3 and NF-κB proteins (index of their activation) in HK2 cells 
(Fig. 10, 11). Moreover, SOD-mimetic tempol treatment attenuated nuclear 
accumulation of both of these transcription factors, suggesting role of superoxide 
in this phenomenon. There are reports attributing either lysine acetylation and/or 
serine phosphorylation as being the mechanism of nuclear translocation of 
transcription factors (Ehlting et al., 2005; Pages, 2007). Therefore, we 
determined lysine-acetylation and phosphorylation of Sp3 in nuclear fractions of 
renal tissues and found lysine-acetylation of Sp3 as a mechanism of its activation 
in response to superoxide (DETC effect).   
Modulation of redox-sensitive transcription factors has been implicated in 
pathological conditions such as atherosclerosis, hypertension, diabetes and other 
cardiovascular disorders (C. K. Sen & Packer, 1996). Recent in vitro studies 
evidenced that oxidative stress activates Sp3 transcription factor (Lee et al., 
2006; Ryu et al., 2003) that in turn increases AT1 receptor transcription. 
However, the link between Sp3 and AT1 receptor up-regulation is not well 
known. Computer analysis and EMSA assays have demonstrated that 
transcription factor Sp3 binds at the AT1 receptor promoter and regulates its 
gene expression (Kambe et al., 2004). We also found that Sp3 plasmid 
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increases, while its depletion with Sp3 siRNA decreases AT1 protein levels in 
HK2 cells (Fig. 14, 15). Studies conducted in Zhao et el lab reported similar 
results showing that Sp3 transcription factor regulate basal AT1 receptor 
expression in H295-R cell line (Zhao et al., 2000, 2001).  
NF-κB is another redox-sensitive transcription factor involved in the 
modulation of myriad of genes responsible for stress and immune responses, 
apoptosis, and cell proliferation and survival (Hayden & Ghosh, 2004). Recent 
studies including ours have shown that NF-κB is also involved in cellular 
antioxidant defenses (Gomez-Cabrera, Domenech, & Vina, 2008; Laughlin et al., 
1990; Lavrovsky, Song, Chatterjee, & Roy, 2000; Morceau et al., 2004) and 
helps attenuates blood pressure by improving kidney function (L. George et al., 
2009; L. E. George et al., 2012). Numerous studies have implicated NF-κB in the 
regulation of renal AT1 receptor gene (Bhatt et al., 2014). Therefore, we became 
interested to determine role of NF-κB in the regulation of AT1 receptor in HK2 
cells. Our transfection studies with NF-κB plasmid showed no increment in renal 
AT1 receptor protein expression, suggesting that NF-κB transcription factor might 
not be involved in the regulation of renal AT1 receptor at least in HK2 cells (Fig. 
20). In order to further investigate the effect of NF-κB on AT1 receptor mRNA 
expression, we knockdown NF-κB using NF-κB shRNA and NF-κB inhibitor 
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PDTC. To our surprise we found that depletion of NF-κB gene expression results 
into increased AT1 receptor mRNA expression (Fig. 21), suggesting an inhibitory 
effect of NF-κB transcription factor on the regulation of AT1 gene expression in 
human kidney cells. Further studies are warranted to confirm the role of NF-κB in 
renal AT1 receptor gene regulation.  
           As mentioned earlier that a number of studies reported that superoxide 
and H2O2 are the main ROS in causing oxidative stress contributing to high blood 
pressure or hypertension (Jutooru et al., 2014; Landmesser et al., 2002; Vaziri, 
Dicus, et al., 2003; Vaziri, Lin, et al., 2003). Moreover, a recent study including 
ours have shown that oxidative stress up-regulates renal AT1 receptor function 
and contributes to high blood pressure or hypertension (Chugh et al., 2011, 
2012; Q. Su et al., 2016; Sungkaworn, Lenbury, & Chatsudthipong, 2011). In 
contrast, some other studies reported that H2O2 is a vasodilator and attenuates 
hypertension (Y. Chen et al., 2007; Park et al., 2015; Schroder et al., 2012). To 
our knowledge, specificity of ROS (superoxide vs. H2O2) in the up-regulation of 
renal AT1 receptor function has not been investigated. To test the specificity of 
superoxide and H2O2 in the up-regulation of renal AT1 receptor expression and 
function, we conducted studies in HK2 cells. First, we measured AT1 receptor 
mRNA expression and found that superoxide (DETC effect) increased mRNA 
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expression (Fig. 12). This effect was attenuated by SOD-mimetic tempol 
suggesting role of superoxide in over-expression of renal AT1 receptor mRNA 
(Fig. 12). H2O2 failed to increase AT1 receptor mRNA levels suggesting that H2O2 
perhaps does not play a role in this phenomenon in HK2 cells (Fig. 12) To 
correlate mRNA data we measured AT1 receptor protein levels and found that 
superoxide (DETC effect) also increased the levels of AT1 receptor protein (Fig. 
13). This effect was attenuated with SOD-mimetic tempol (Fig. 13). Interestingly, 
superoxide (DETC) mediated Sp3 activation was associated with an increase in 
renal AT1 receptor mRNA and protein expressions in HK2 cells. H2O2 failed to 
cause Sp3 activation and AT1 receptor expressions. Taken together, these 
results suggest that superoxide via Sp3 transcription factor regulates renal AT1 
receptor expression.  
 Functional receptors reside on the cell membranes. Therefore, we 
determined whether DETC (superoxide effect) affects the abundance of 
membranous AT1 receptor levels and its function. The levels of membranous 
AT1 receptors were determined by biotinylation and imaging methodological 
approaches. Cell surface membrane proteins were isolated by cross-linking with 
biotin followed by determining AT1 receptor by Western blotting. Our results 
showed that superoxide (DETC effect) increased membranous AT1 receptor 
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protein levels that were attenuated with SOD-mimetic tempol (Fig. 17). Moreover, 
imaging studies demonstrated that superoxide (DETC effect) increased the 
fluorescence levels of AT1 receptor protein in the cell membranes, and SOD-
mimetic tempol attenuated this effect of superoxide [(DETC effect) (Fig. 18)]. 
These results suggest that superoxide (DETC effect) increases cellular as well as 
membranous levels of AT1 receptor. Finally, to examine whether superoxide-
induced increase in the levels of membranous AT1 receptor is functional, PKC 
activity in response to AT1 receptor ligand ang II was measured. Measuring PKC 
activity in response to ang II is an index of AT1 receptor function (Mehta and 
Griendling 2007, (I. D. Pokkunuri et al., 2013). We found that ang II increased 
PKC activity in the absence of DETC, which was more pronounced in DETC 
treated cells (Fig. 19). This effect was attenuated by SOD-mimetic tempol and 
AT1 receptor blocker candesartan (Fig. 19). These results suggest that 
superoxide induced (DETC effect) increase in the levels of membranous AT1 
receptors are functional. Also, these results suggest that increase in PKC activity 
is superoxide and AT1 receptor specific as SOD-mimetic tempol and 
candesartan attenuate ang II response on PKC, respectively (Fig. 15). To 
determine whether superoxide (DETC effect) involves Sp3 transcription factor in 
regulating expression of renal AT1 receptor protein, HK2 cells were transfected 
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with and without Sp3 siRNA followed by treatment with DETC. We found that 
superoxide (DETC effect) in the absence of Sp3 siRNA increased the levels of 
AT1 receptor proteins, which were attenuated in the presence of Sp3 siRNA (Fig. 
16). These results suggest that superoxide via Sp3 transcription factor increases 
renal AT1 receptor protein levels. 
Cell culture systems are powerful tool to corroborate findings in animal 
models. However, cell culture systems pose limitations when it comes to 
measuring blood pressure. Therefore, we became interested in examining 
whether superoxide (DETC effect) regulates blood pressure and renal AT1 
receptor function in an animal model. Sprague Dawley rats were treated with 
DETC that by inhibiting SOD increases superoxide levels. Many labs have used 
DETC to generate superoxide in rats (Gupta & Sharma, 2014; Matsumura et al., 
2001). Therefore, we first determined superoxide levels in renal tissues of DETC 
treated rats using superoxide probe DHE as used in cell culture studies.  We 
found higher levels of superoxide in DETC-treated compared to vehicle-treated 
rats (Fig. 24). DETC induced increase in superoxide levels were reduced in renal 
tissues of rats treated with SOD mimetic tempol (Fig. 24). SOD mimetic tempol 
has been used as an antioxidant in various hypertensive animal models (Chugh 
et al., 2011; Wilcox, 2010). Further, using H2O2 probe DCFHDA we found that 
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DETC does not increase H2O2 levels in renal tissues of DETC treated rats (Fig. 
25). Again, these results suggest that DETC specifically increases superoxide 
levels in renal tissues as well as in HK2 in cultures (Figs. 24, 8).  
In order to determine role of superoxide in regulation of blood pressure 
and renal AT1 receptor function we measured blood pressure and renal AT1 
receptor function (diuresis and natriuresis in response to AT1 receptor blocker 
candesartan) in vehicle and DETC treated rats. Determining natriuresis and 
diuresis in response to candesartan is an index of renal AT1 receptor function in 
rats (Chugh et al., 2011). We found high blood pressure in vehicle-treated control 
rats, which further increased in DETC treated rats (Fig. 23). DETC (superoxide 
effect) induced increase in blood pressure was attenuated in rats treated with 
SOD mimetic tempol (Fig. 23). These results suggest that superoxide increases 
blood pressure in rats. We do not know the reason for high blood pressure in 
control rats. It could be due to batch of the rats employed in the study.  
Studies from Crowley and Coffman and other groups have demonstrated 
a predominant role of renal AT1 receptor in blood pressure regulation (Coffman & 
Crowley, 2008; Crowley et al., 2005). Furthermore, studies in our lab have shown 
that AT1 receptor blocker candesartan increases diuresis and natriuresis in an 
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aging rat model, aged FBN rats, associated with increased reactive oxygen 
species (ROS, oxidative stress) and high blood pressure (Chugh et al., 2011, 
2012). These studies suggest that increase in the levels of ROS increases renal 
AT1 receptor function and blood pressure. Therefore, we became interested in 
determining role of superoxide (one of the ROS) in the regulation of renal AT1 
receptor function and blood pressure in adult SD rats. We found that AT1 
receptor blocker candesartan increased diuresis and natriuresis in DETC treated 
SD rats, suggesting that AT1 receptor function is exaggerated in these rats (Figs. 
26, 27). Interestingly, SOD-mimetic tempol reduced diuresis and natriuresis in 
response to candesartan in DETC treated rats (Figs. 26, 27), suggesting 
involvement of superoxide in exaggerated AT1 receptor function. Previous 
studies from our lab reported that rats exhibiting high levels of oxidative stress 
showed Na/K ATPase reduction upon candesartan treatment thereby increased 
sodium excretion or natriuresis in renal proximal tubules (RPTs) (Banday & 
Lokhandwala, 2008b). Based on these studies, we speculate that increased 
natriuresis upon candesartan treatment is due to the reduction of exaggerated 
Na/K ATPase activity in RPTs of DETC rats. 
Lysine acetylation (Ehlting et al., 2005) and serine-73 phosphorylation 
(Pages, 2007) are attributed to the activation of Sp3 transcription factors. 
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Therefore, we determined lysine-acetylation and serine-phosphorylation of Sp3 in 
the renal nuclear extracts of rats. We measured pan-serine-phosphorylation of 
Sp3, phosphoserine-73 specific antibody was not available. We found increased 
lysine-acetylated Sp3 in DETC treated rats compared to control rats. SOD-
mimetic tempol reduced the levels of lysine-acetylated Sp3 in DETC -treated rats 
(Fig 28A). On the other hand, we did not find any change in the phosphorylation 
levels of Sp3 in DETC-treated compared to vehicle-treated or tempol-treated rats 
(Fig 28B). These results suggest that superoxide (DETC effect) by acetylating 
lysine residue of Sp3 activates the transcription factor.   
Based upon our findings from cell culture and animal studies, we propose 
that superoxide by lysine-acetylating Sp3 activates the transcription factor. 
Activated Sp3 translocates to the nucleus and increases AT1 receptor mRNA 
and protein levels. Increased levels of cellular AT1 receptors increase 
membranous levels of AT1 receptor that amplifies AT1 receptor response and 
contributes to hypertension.  
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6. SUMMARY AND CONCLUSIONS  
In vitro studies (HK2 cells) 
1. Our results demonstrate that DHE and DCFHDA probes specifically detect 
superoxide and hydrogen peroxide respectively.  
2. Superoxide but not hydrogen peroxide increases nuclear levels of Sp3, 
and NF-κB transcription factors.  
3. Sp3 plasmid increases while Sp3 siRNA decreases AT1 receptor protein 
expression. 
4. Superoxide increases the levels of AT1 receptor mRNA and protein 
expressions. However, hydrogen peroxide fails to increase AT1 receptor 
mRNA expression. 
5. Sp3 siRNA reduced AT1 receptor protein expression even in the presence 
of increased superoxide levels.  
6. Superoxide in response to Ang II exaggerates PKC activity (an index of 
measuring AT1 receptor function), which is attenuated both with AT1 
receptor blocker candesartan and tempol. 
7. NF-κB transcription factor does not show any significant effect on AT1 
receptor protein expression, suggesting that this transcription factor does 
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not up-regulate AT1 receptor protein in HK2 cells. 
 
Animal studies (SD rats) 
8. DETC treatment increases superoxide levels in KSC as measured by DHE 
probe. However, levels of hydrogen peroxide are not higher in DETC 
treated rats as measured by DCFHDA probe. These results are in 
consensus with our cell culture studies. 
9. Superoxide caused increased acetylation of Sp3 transcription factor in 
KSC. 
10. Candesartan infusion increases diuresis and natriuresis in DETC treated 
rats, suggesting high levels of superoxide increases AT1 receptor 
function.  
11. Superoxide (DETC treatment) increases blood pressure in SD rats as 
measured carotid artery catheterization. 
 
 
 
	  	  
	  
	  
	  
	  
117	  	  
	  
	  
	  
 
7. REFERENCES 
Al Ghouleh, I., Khoo, N. K., Knaus, U. G., Griendling, K. K., Touyz, R. M., 
Thannickal, V. J., Pagano, P. J. (2011). Oxidases and peroxidases in 
cardiovascular and lung disease: new concepts in reactive oxygen species 
signaling. Free Radic Biol Med, 51(7), 1271-1288. 
doi:10.1016/j.freeradbiomed.2011.06.011 
Allum, W. H., Hallissey, M. T., Ward, L. C., & Hockey, M. S. (1989). A controlled, 
prospective, randomised trial of adjuvant chemotherapy or radiotherapy in 
resectable gastric cancer: interim report. British Stomach Cancer Group. Br J 
Cancer, 60(5), 739-744.  
Ammanamanchi, S., Freeman, J. W., & Brattain, M. G. (2003). Acetylated sp3 is 
a transcriptional activator. J Biol Chem, 278(37), 35775-35780. 
doi:10.1074/jbc.M305961200 
Atchison, M. L., & Perry, R. P. (1987). The role of the kappa enhancer and its 
binding factor NF-kappa B in the developmental regulation of kappa gene 
transcription. Cell, 48(1), 121-128.  
	  	  
	  
	  
	  
	  
118	  	  
	  
	  
	  
Banday, A. A., Fazili, F. R., & Lokhandwala, M. F. (2007). Oxidative stress 
causes renal dopamine D1 receptor dysfunction and hypertension via 
mechanisms that involve nuclear factor-kappaB and protein kinase C. J Am Soc 
Nephrol, 18(5), 1446-1457. doi:10.1681/ASN.2006121373 
Banday, A. A., Lau, Y. S., & Lokhandwala, M. F. (2008). Oxidative stress causes 
renal dopamine D1 receptor dysfunction and salt-sensitive hypertension in 
Sprague-Dawley rats. Hypertension, 51(2), 367-375. 
doi:10.1161/HYPERTENSIONAHA.107.102111 
Banday, A. A., & Lokhandwala, M. F. (2008a). Loss of biphasic effect on Na/K-
ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-
nitric oxide signaling. Hypertension, 52(6), 1099-1105. 
doi:10.1161/HYPERTENSIONAHA.108.117911 
Banday, A. A., & Lokhandwala, M. F. (2008b). Oxidative stress-induced renal 
angiotensin AT1 receptor upregulation causes increased stimulation of sodium 
transporters and hypertension. Am J Physiol Renal Physiol, 295(3), F698-706. 
doi:10.1152/ajprenal.90308.2008 
Banday, A. A., & Lokhandwala, M. F. (2015). Transcriptional regulation of renal 
dopamine D1 receptor function during oxidative stress. Hypertension, 65(5), 
	  	  
	  
	  
	  
	  
119	  	  
	  
	  
	  
1064-1072. doi:10.1161/HYPERTENSIONAHA.115.05255 
Barchowsky, A., Munro, S. R., Morana, S. J., Vincenti, M. P., & Treadwell, M. 
(1995). Oxidant-sensitive and phosphorylation-dependent activation of NF-kappa 
B and AP-1 in endothelial cells. Am J Physiol, 269(6 Pt 1), L829-836.  
Bhatt, S. R., Lokhandwala, M. F., & Banday, A. A. (2014). Vascular oxidative 
stress upregulates angiotensin II type I receptors via mechanisms involving 
nuclear factor kappa B. Clin Exp Hypertens, 36(6), 367-373. 
doi:10.3109/10641963.2014.943402 
Birns, J., & Kalra, L. (2009). Cognitive function and hypertension. J Hum 
Hypertens, 23(2), 86-96. doi:10.1038/jhh.2008.80 
Bouwman, P., Gollner, H., Elsasser, H. P., Eckhoff, G., Karis, A., Grosveld, F., . . 
. Suske, G. (2000). Transcription factor Sp3 is essential for post-natal survival 
and late tooth development. EMBO J, 19(4), 655-661. 
doi:10.1093/emboj/19.4.655 
Caner, M., Karter, Y., Uzun, H., Curgunlu, A., Vehid, S., Balci, H., . . . Ozturk, E. 
(2006). Oxidative stress in human in sustained and white coat hypertension. Int J 
Clin Pract, 60(12), 1565-1571. doi:10.1111/j.1742-1241.2006.00959.x 
	  	  
	  
	  
	  
	  
120	  	  
	  
	  
	  
Chabrashvili, T., Tojo, A., Onozato, M. L., Kitiyakara, C., Quinn, M. T., Fujita, T., . 
. . Wilcox, C. S. (2002). Expression and cellular localization of classic NADPH 
oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension, 
39(2), 269-274.  
Chen, K., Xie, F., Liu, S., Li, G., Chen, Y., Shi, W., . . . Yin, D. (2011). Plasma 
reactive carbonyl species: Potential risk factor for hypertension. Free Radic Res, 
45(5), 568-574. doi:10.3109/10715762.2011.557723 
Chen, X., Touyz, R. M., Park, J. B., & Schiffrin, E. L. (2001). Antioxidant effects 
of vitamins C and E are associated with altered activation of vascular NADPH 
oxidase and superoxide dismutase in stroke-prone SHR. Hypertension, 38(3 Pt 
2), 606-611.  
Chen, Y., Pearlman, A., Luo, Z., & Wilcox, C. S. (2007). Hydrogen peroxide 
mediates a transient vasorelaxation with tempol during oxidative stress. Am J 
Physiol Heart Circ Physiol, 293(4), H2085-2092. 
doi:10.1152/ajpheart.00968.2006 
Chen, Z. J., Parent, L., & Maniatis, T. (1996). Site-specific phosphorylation of 
IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell, 
	  	  
	  
	  
	  
	  
121	  	  
	  
	  
	  
84(6), 853-862.  
Chugh, G., Lokhandwala, M. F., & Asghar, M. (2011). Oxidative stress alters 
renal D1 and AT1 receptor functions and increases blood pressure in old rats. 
Am J Physiol Renal Physiol, 300(1), F133-138. doi:10.1152/ajprenal.00465.2010 
Chugh, G., Lokhandwala, M. F., & Asghar, M. (2012). Altered functioning of both 
renal dopamine D1 and angiotensin II type 1 receptors causes hypertension in 
old rats. Hypertension, 59(5), 1029-1036. 
doi:10.1161/HYPERTENSIONAHA.112.192302 
Clem, B. F., & Clark, B. J. (2006). Association of the mSin3A-histone deacetylase 
1/2 corepressor complex with the mouse steroidogenic acute regulatory protein 
gene. Mol Endocrinol, 20(1), 100-113. doi:10.1210/me.2004-0495 
Coffman, T. M., & Crowley, S. D. (2008). Kidney in hypertension: guyton redux. 
Hypertension, 51(4), 811-816. doi:10.1161/HYPERTENSIONAHA.105.063636 
Cowley, A. W., Jr., Mori, T., Mattson, D., & Zou, A. P. (2003). Role of renal NO 
production in the regulation of medullary blood flow. Am J Physiol Regul Integr 
Comp Physiol, 284(6), R1355-1369. doi:10.1152/ajpregu.00701.2002 
Cowling, R. T., Zhang, X., Reese, V. C., Iwata, M., Gurantz, D., Dillmann, W. H., 
	  	  
	  
	  
	  
	  
122	  	  
	  
	  
	  
& Greenberg, B. H. (2005). Effects of cytokine treatment on angiotensin II type 
1A receptor transcription and splicing in rat cardiac fibroblasts. Am J Physiol 
Heart Circ Physiol, 289(3), H1176-1183. doi:10.1152/ajpheart.00088.2005 
Crowley, S. D., & Coffman, T. M. (2012). Recent advances involving the renin-
angiotensin system. Exp Cell Res, 318(9), 1049-1056. 
doi:10.1016/j.yexcr.2012.02.023 
Crowley, S. D., Gurley, S. B., Herrera, M. J., Ruiz, P., Griffiths, R., Kumar, A. P., . 
. . Coffman, T. M. (2006). Angiotensin II causes hypertension and cardiac 
hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A, 
103(47), 17985-17990. doi:10.1073/pnas.0605545103 
Crowley, S. D., Gurley, S. B., Oliverio, M. I., Pazmino, A. K., Griffiths, R., 
Flannery, P. J., . . . Coffman, T. M. (2005). Distinct roles for the kidney and 
systemic tissues in blood pressure regulation by the renin-angiotensin system. J 
Clin Invest, 115(4), 1092-1099.  
Crowley, S. D., Tharaux, P. L., Audoly, L. P., & Coffman, T. M. (2004). Exploring 
type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol 
Scand, 181(4), 561-570. doi:10.1111/j.1365-201X.2004.01331.x 
	  	  
	  
	  
	  
	  
123	  	  
	  
	  
	  
Davie, J. R., He, S., Li, L., Sekhavat, A., Espino, P., Drobic, B., . . . Wang, X. 
(2008). Nuclear organization and chromatin dynamics--Sp1, Sp3 and histone 
deacetylases. Adv Enzyme Regul, 48, 189-208. 
doi:10.1016/j.advenzreg.2007.11.016 
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000). 
International union of pharmacology. XXIII. The angiotensin II receptors. 
Pharmacol Rev, 52(3), 415-472.  
DeWire, S. M., Ahn, S., Lefkowitz, R. J., & Shenoy, S. K. (2007). Beta-arrestins 
and cell signaling. Annu Rev Physiol, 69, 483-510. 
doi:10.1146/annurev.ph.69.013107.100021 
Dickhout, J. G., Mori, T., & Cowley, A. W., Jr. (2002). Tubulovascular nitric oxide 
crosstalk: buffering of angiotensin II-induced medullary vasoconstriction. Circ 
Res, 91(6), 487-493.  
Dorfmuller, P., Chaumais, M. C., Giannakouli, M., Durand-Gasselin, I., Raymond, 
N., Fadel, E., . . . Perros, F. (2011). Increased oxidative stress and severe 
arterial remodeling induced by permanent high-flow challenge in experimental 
pulmonary hypertension. Respir Res, 12, 119. doi:10.1186/1465-9921-12-119 
	  	  
	  
	  
	  
	  
124	  	  
	  
	  
	  
Droge, W. (2002). Free radicals in the physiological control of cell function. 
Physiol Rev, 82(1), 47-95. doi:10.1152/physrev.00018.2001 
Ehlting, C., Haussinger, D., & Bode, J. G. (2005). Sp3 is involved in the 
regulation of SOCS3 gene expression. Biochem J, 387(Pt 3), 737-745. 
doi:10.1042/BJ20041101 
Elton, T. S., & Martin, M. M. (2007). Angiotensin II type 1 receptor gene 
regulation: transcriptional and posttranscriptional mechanisms. Hypertension, 
49(5), 953-961. doi:10.1161/HYPERTENSIONAHA.106.070565 
Farbstein, D., Kozak-Blickstein, A., & Levy, A. P. (2010). Antioxidant vitamins 
and their use in preventing cardiovascular disease. Molecules, 15(11), 8098-
8110. doi:10.3390/molecules15118098 
Fellner, S. K., & Arendshorst, W. J. (2005). Angiotensin II, reactive oxygen 
species, and Ca2+ signaling in afferent arterioles. Am J Physiol Renal Physiol, 
289(5), F1012-1019. doi:10.1152/ajprenal.00144.2005 
Fukai, T., & Ushio-Fukai, M. (2011). Superoxide dismutases: role in redox 
signaling, vascular function, and diseases. Antioxid Redox Signal, 15(6), 1583-
1606. doi:10.1089/ars.2011.3999 
	  	  
	  
	  
	  
	  
125	  	  
	  
	  
	  
Galbusera, C., Orth, P., Fedida, D., & Spector, T. (2006). Superoxide radical 
production by allopurinol and xanthine oxidase. Biochem Pharmacol, 71(12), 
1747-1752. doi:10.1016/j.bcp.2006.02.008 
George, L., Lokhandwala, M. F., & Asghar, M. (2009). Exercise activates redox-
sensitive transcription factors and restores renal D1 receptor function in old rats. 
Am J Physiol Renal Physiol, 297(5), F1174-1180. 
doi:10.1152/ajprenal.00397.2009 
George, L. E., Lokhandwala, M. F., & Asghar, M. (2012). Novel role of NF-
kappaB-p65 in antioxidant homeostasis in human kidney-2 cells. Am J Physiol 
Renal Physiol, 302(11), F1440-1446. doi:10.1152/ajprenal.00006.2012 
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. 
J., . . . Stroke Statistics, S. (2014). Heart disease and stroke statistics--2014 
update: a report from the American Heart Association. Circulation, 129(3), e28-
e292. doi:10.1161/01.cir.0000441139.02102.80 
Gomez-Cabrera, M. C., Domenech, E., & Vina, J. (2008). Moderate exercise is 
an antioxidant: upregulation of antioxidant genes by training. Free Radic Biol 
Med, 44(2), 126-131. doi:10.1016/j.freeradbiomed.2007.02.001 
	  	  
	  
	  
	  
	  
126	  	  
	  
	  
	  
Gongora, M. C., Qin, Z., Laude, K., Kim, H. W., McCann, L., Folz, J. R., . . . 
Harrison, D. G. (2006). Role of extracellular superoxide dismutase in 
hypertension. Hypertension, 48(3), 473-481. 
doi:10.1161/01.HYP.0000235682.47673.ab 
Gori, T., & Munzel, T. (2011). Oxidative stress and endothelial dysfunction: 
therapeutic implications. Ann Med, 43(4), 259-272. 
doi:10.3109/07853890.2010.543920 
Gough, D. R., & Cotter, T. G. (2011). Hydrogen peroxide: a Jekyll and Hyde 
signalling molecule. Cell Death Dis, 2, e213. doi:10.1038/cddis.2011.96 
Goyal, M. M., & Basak, A. (2010). Human catalase: looking for complete identity. 
Protein Cell, 1(10), 888-897. doi:10.1007/s13238-010-0113-z 
Gupta, S., & Sharma, B. (2014). Pharmacological benefit of I(1)-imidazoline 
receptors activation and nuclear factor kappa-B (NF-kappaB) modulation in 
experimental Huntington's disease. Brain Res Bull, 102, 57-68. 
doi:10.1016/j.brainresbull.2014.02.007 
Gurley, S. B., Riquier-Brison, A. D., Schnermann, J., Sparks, M. A., Allen, A. M., 
Haase, V. H., . . . Coffman, T. M. (2011). AT1A angiotensin receptors in the renal 
	  	  
	  
	  
	  
	  
127	  	  
	  
	  
	  
proximal tubule regulate blood pressure. Cell Metab, 13(4), 469-475. 
doi:10.1016/j.cmet.2011.03.001 
Guyton, A. C. (1991). Blood pressure control--special role of the kidneys and 
body fluids. Science, 252(5014), 1813-1816.  
Hagen, G., Muller, S., Beato, M., & Suske, G. (1992). Cloning by recognition site 
screening of two novel GT box binding proteins: a family of Sp1 related genes. 
Nucleic Acids Res, 20(21), 5519-5525.  
Hall, J. E. (1986). Control of sodium excretion by angiotensin II: intrarenal 
mechanisms and blood pressure regulation. Am J Physiol, 250(6 Pt 2), R960-
972.  
Hall, J. E. (1991). The renin-angiotensin system: renal actions and blood 
pressure regulation. Compr Ther, 17(5), 8-17.  
Harrison, D. G., & Gongora, M. C. (2009). Oxidative stress and hypertension. 
Med Clin North Am, 93(3), 621-635. doi:10.1016/j.mcna.2009.02.015 
Hayden, M. S., & Ghosh, S. (2004). Signaling to NF-kappaB. Genes Dev, 18(18), 
2195-2224. doi:10.1101/gad.1228704 
	  	  
	  
	  
	  
	  
128	  	  
	  
	  
	  
Hayden, M. S., & Ghosh, S. (2008). Shared principles in NF-kappaB signaling. 
Cell, 132(3), 344-362. doi:10.1016/j.cell.2008.01.020 
Hayot, F., & Jayaprakash, C. (2006). NF-kappaB oscillations and cell-to-cell 
variability. J Theor Biol, 240(4), 583-591. doi:10.1016/j.jtbi.2005.10.018 
He, S., Sun, J. M., Li, L., & Davie, J. R. (2005). Differential intranuclear 
organization of transcription factors Sp1 and Sp3. Mol Biol Cell, 16(9), 4073-
4083. doi:10.1091/mbc.E05-05-0388 
Heinemeyer, T., Wingender, E., Reuter, I., Hermjakob, H., Kel, A. E., Kel, O. V., 
Kolchanov, N. A. (1998). Databases on transcriptional regulation: TRANSFAC, 
TRRD and COMPEL. Nucleic Acids Res, 26(1), 362-367.  
Jutooru, I., Guthrie, A. S., Chadalapaka, G., Pathi, S., Kim, K., Burghardt, R., . . . 
Safe, S. (2014). Mechanism of action of phenethylisothiocyanate and other 
reactive oxygen species-inducing anticancer agents. Mol Cell Biol, 34(13), 2382-
2395. doi:10.1128/MCB.01602-13 
Kambe, T., Kinjyo, N., Hiruki, H., & Kubo, T. (2004). Basal transcriptional 
regulation of rat AT1 angiotensin II receptor gene expression. Clin Exp 
Pharmacol Physiol, 31(1-2), 96-100.  
	  	  
	  
	  
	  
	  
129	  	  
	  
	  
	  
Kim, A. D., Kang, K. A., Piao, M. J., Kim, K. C., Zheng, J., Yao, C. W., Hyun, J. 
W. (2014). Cytoprotective effect of eckol against oxidative stress-induced 
mitochondrial dysfunction: involvement of the FoxO3a/AMPK pathway. J Cell 
Biochem, 115(8), 1403-1411. doi:10.1002/jcb.24790 
Kim, K., Chadalapaka, G., Lee, S. O., Yamada, D., Sastre-Garau, X., Defossez, 
P. A., Safe, S. (2012). Identification of oncogenic microRNA-17-
92/ZBTB4/specificity protein axis in breast cancer. Oncogene, 31(8), 1034-1044. 
doi:10.1038/onc.2011.296 
Kizhakekuttu, T. J., & Widlansky, M. E. (2010). Natural antioxidants and 
hypertension: promise and challenges. Cardiovasc Ther, 28(4), e20-32. 
doi:10.1111/j.1755-5922.2010.00137.x 
Kobori, H., Nangaku, M., Navar, L. G., & Nishiyama, A. (2007). The intrarenal 
renin-angiotensin system: from physiology to the pathobiology of hypertension 
and kidney disease. Pharmacol Rev, 59(3), 251-287. doi:10.1124/pr.59.3.3 
Kopkan, L., Castillo, A., Navar, L. G., & Majid, D. S. (2006). Enhanced 
superoxide generation modulates renal function in ANG II-induced hypertensive 
rats. Am J Physiol Renal Physiol, 290(1), F80-86. 
	  	  
	  
	  
	  
	  
130	  	  
	  
	  
	  
doi:10.1152/ajprenal.00090.2005 
Kruger, I., Vollmer, M., Simmons, D. G., Elsasser, H. P., Philipsen, S., & Suske, 
G. (2007). Sp1/Sp3 compound heterozygous mice are not viable: impaired 
erythropoiesis and severe placental defects. Dev Dyn, 236(8), 2235-2244. 
doi:10.1002/dvdy.21222 
Kubo, T., Kinjyo, N., Ikezawa, A., Kambe, T., & Fukumori, R. (2003). Sp1 decoy 
oligodeoxynucleotide decreases angiotensin receptor expression and blood 
pressure in spontaneously hypertensive rats. Brain Res, 992(1), 1-8.  
Lacy, F., Gough, D. A., & Schmid-Schonbein, G. W. (1998). Role of xanthine 
oxidase in hydrogen peroxide production. Free Radic Biol Med, 25(6), 720-727.  
Lacy, F., Kailasam, M. T., O'Connor, D. T., Schmid-Schonbein, G. W., & Parmer, 
R. J. (2000). Plasma hydrogen peroxide production in human essential 
hypertension: role of heredity, gender, and ethnicity. Hypertension, 36(5), 878-
884.  
Lacy, F., O'Connor, D. T., & Schmid-Schonbein, G. W. (1998). Plasma hydrogen 
peroxide production in hypertensives and normotensive subjects at genetic risk 
of hypertension. J Hypertens, 16(3), 291-303.  
	  	  
	  
	  
	  
	  
131	  	  
	  
	  
	  
Landmesser, U., Cai, H., Dikalov, S., McCann, L., Hwang, J., Jo, H., . . . 
Harrison, D. G. (2002). Role of p47(phox) in vascular oxidative stress and 
hypertension caused by angiotensin II. Hypertension, 40(4), 511-515.  
Lapo, R. A., Gogny, M., Chatagnon, G., Lalanne, V., Harfoush, K., Assane, M., 
Mallem, M. Y. (2014). Equine digital veins are more sensitive to superoxide 
anions than digital arteries. Eur J Pharmacol, 740, 66-71. 
doi:10.1016/j.ejphar.2014.06.016 
Lasagni Vitar, R. M., Tau, J., Reides, C. G., Berra, A., Ferreira, S. M., & Llesuy, 
S. F. (2015). Evaluation of Oxidative Stress Markers in Human Conjunctival 
Epithelial Cells Exposed to Diesel Exhaust Particles (DEP). Invest Ophthalmol 
Vis Sci, 56(12), 7058-7066. doi:10.1167/iovs.15-16864 
Lassegue, B., & Griendling, K. K. (2004). Reactive oxygen species in 
hypertension; An update. Am J Hypertens, 17(9), 852-860. 
doi:10.1016/j.amjhyper.2004.02.004 
Laughlin, M. H., Simpson, T., Sexton, W. L., Brown, O. R., Smith, J. K., & 
Korthuis, R. J. (1990). Skeletal muscle oxidative capacity, antioxidant enzymes, 
and exercise training. J Appl Physiol (1985), 68(6), 2337-2343.  
	  	  
	  
	  
	  
	  
132	  	  
	  
	  
	  
Lavrovsky, Y., Chatterjee, B., Clark, R. A., & Roy, A. K. (2000). Role of redox-
regulated transcription factors in inflammation, aging and age-related diseases. 
Exp Gerontol, 35(5), 521-532.  
Lavrovsky, Y., Song, C. S., Chatterjee, B., & Roy, A. K. (2000). Age-dependent 
increase of heme oxygenase-1 gene expression in the liver mediated by 
NFkappaB. Mech Ageing Dev, 114(1), 49-60.  
Lawes, C. M., Vander Hoorn, S., Rodgers, A., & International Society of, H. 
(2008). Global burden of blood-pressure-related disease, 2001. Lancet, 
371(9623), 1513-1518. doi:10.1016/S0140-6736(08)60655-8 
Lee, J., Kosaras, B., Aleyasin, H., Han, J. A., Park, D. S., Ratan, R. R., Ryu, H. 
(2006). Role of cyclooxygenase-2 induction by transcription factor Sp1 and Sp3 
in neuronal oxidative and DNA damage response. FASEB J, 20(13), 2375-2377. 
doi:10.1096/fj.06-5957fje 
Lerner, L. E., Peng, G. H., Gribanova, Y. E., Chen, S., & Farber, D. B. (2005). 
Sp4 is expressed in retinal neurons, activates transcription of photoreceptor-
specific genes, and synergizes with Crx. J Biol Chem, 280(21), 20642-20650. 
doi:10.1074/jbc.M500957200 
	  	  
	  
	  
	  
	  
133	  	  
	  
	  
	  
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993). The effect of 
angiotensin-converting-enzyme inhibition on diabetic nephropathy. The 
Collaborative Study Group. N Engl J Med, 329(20), 1456-1462. 
doi:10.1056/NEJM199311113292004 
Li, L., He, S., Sun, J. M., & Davie, J. R. (2004). Gene regulation by Sp1 and Sp3. 
Biochem Cell Biol, 82(4), 460-471. doi:10.1139/o04-045 
Li, X. C., & Zhuo, J. L. (2008). Nuclear factor-kappaB as a hormonal intracellular 
signaling molecule: focus on angiotensin II-induced cardiovascular and renal 
injury. Curr Opin Nephrol Hypertens, 17(1), 37-43. 
doi:10.1097/MNH.0b013e3282f2903c 
Lifton, R. P., Gharavi, A. G., & Geller, D. S. (2001). Molecular mechanisms of 
human hypertension. Cell, 104(4), 545-556.  
Liu, R., Ren, Y., Garvin, J. L., & Carretero, O. A. (2004). Superoxide enhances 
tubuloglomerular feedback by constricting the afferent arteriole. Kidney Int, 66(1), 
268-274. doi:10.1111/j.1523-1755.2004.00727.x 
Marin, M., Karis, A., Visser, P., Grosveld, F., & Philipsen, S. (1997). Transcription 
factor Sp1 is essential for early embryonic development but dispensable for cell 
	  	  
	  
	  
	  
	  
134	  	  
	  
	  
	  
growth and differentiation. Cell, 89(4), 619-628.  
Mastrangelo, I. A., Courey, A. J., Wall, J. S., Jackson, S. P., & Hough, P. V. 
(1991). DNA looping and Sp1 multimer links: a mechanism for transcriptional 
synergism and enhancement. Proc Natl Acad Sci U S A, 88(13), 5670-5674.  
Matsumura, N., Ochi, K., Ichimura, M., Mizushima, T., Harada, H., & Harada, M. 
(2001). Study on free radicals and pancreatic fibrosis--pancreatic fibrosis induced 
by repeated injections of superoxide dismutase inhibitor. Pancreas, 22(1), 53-57.  
Meng, S., Cason, G. W., Gannon, A. W., Racusen, L. C., & Manning, R. D., Jr. 
(2003). Oxidative stress in Dahl salt-sensitive hypertension. Hypertension, 41(6), 
1346-1352. doi:10.1161/01.HYP.0000070028.99408.E8 
Miriyala, S., Spasojevic, I., Tovmasyan, A., Salvemini, D., Vujaskovic, Z., St 
Clair, D., & Batinic-Haberle, I. (2012). Manganese superoxide dismutase, 
MnSOD and its mimics. Biochim Biophys Acta, 1822(5), 794-814. 
doi:10.1016/j.bbadis.2011.12.002 
Mitra, A. K., Gao, L., & Zucker, I. H. (2010). Angiotensin II-induced upregulation 
of AT(1) receptor expression: sequential activation of NF-kappaB and Elk-1 in 
neurons. Am J Physiol Cell Physiol, 299(3), C561-569. 
	  	  
	  
	  
	  
	  
135	  	  
	  
	  
	  
doi:10.1152/ajpcell.00127.2010 
Miura, H., Bosnjak, J. J., Ning, G., Saito, T., Miura, M., & Gutterman, D. D. 
(2003). Role for hydrogen peroxide in flow-induced dilation of human coronary 
arterioles. Circ Res, 92(2), e31-40.  
Montezano, A. C., & Touyz, R. M. (2012). Molecular mechanisms of 
hypertension--reactive oxygen species and antioxidants: a basic science update 
for the clinician. Can J Cardiol, 28(3), 288-295. doi:10.1016/j.cjca.2012.01.017 
Montezano, A. C., & Touyz, R. M. (2014). Reactive oxygen species, vascular 
Noxs, and hypertension: focus on translational and clinical research. Antioxid 
Redox Signal, 20(1), 164-182. doi:10.1089/ars.2013.5302 
Morceau, F., Duvoix, A., Delhalle, S., Schnekenburger, M., Dicato, M., & 
Diederich, M. (2004). Regulation of glutathione S-transferase P1-1 gene 
expression by NF-kappaB in tumor necrosis factor alpha-treated K562 leukemia 
cells. Biochem Pharmacol, 67(7), 1227-1238. doi:10.1016/j.bcp.2003.10.036 
Mori, T., & Cowley, A. W., Jr. (2003). Angiotensin II-NAD(P)H oxidase-stimulated 
superoxide modifies tubulovascular nitric oxide cross-talk in renal outer medulla. 
Hypertension, 42(4), 588-593. doi:10.1161/01.HYP.0000091821.39824.09 
	  	  
	  
	  
	  
	  
136	  	  
	  
	  
	  
Munzel, T., Daiber, A., Ullrich, V., & Mulsch, A. (2005). Vascular consequences 
of endothelial nitric oxide synthase uncoupling for the activity and expression of 
the soluble guanylyl cyclase and the cGMP-dependent protein kinase. 
Arterioscler Thromb Vasc Biol, 25(8), 1551-1557. 
doi:10.1161/01.ATV.0000168896.64927.bb 
Murphey, L. J., Morrow, J. D., Sawathiparnich, P., Williams, G. H., Vaughan, D. 
E., & Brown, N. J. (2003). Acute angiotensin II increases plasma F2-isoprostanes 
in salt-replete human hypertensives. Free Radic Biol Med, 35(7), 711-718.  
Nagao, A. (2011). Absorption and metabolism of dietary carotenoids. Biofactors, 
37(2), 83-87. doi:10.1002/biof.151 
Nair, V., Sreevalsan, S., Basha, R., Abdelrahim, M., Abudayyeh, A., Rodrigues 
Hoffman, A., & Safe, S. (2014). Mechanism of metformin-dependent inhibition of 
mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: 
role of specificity protein (Sp) transcription factors. J Biol Chem, 289(40), 27692-
27701. doi:10.1074/jbc.M114.592576 
Nakazono, K., Watanabe, N., Matsuno, K., Sasaki, J., Sato, T., & Inoue, M. 
(1991). Does superoxide underlie the pathogenesis of hypertension? Proc Natl 
	  	  
	  
	  
	  
	  
137	  	  
	  
	  
	  
Acad Sci U S A, 88(22), 10045-10048.  
Navar, L. G. (2005). The role of the kidneys in hypertension. J Clin Hypertens 
(Greenwich), 7(9), 542-549.  
Navar, L. G., Harrison-Bernard, L. M., Wang, C. T., Cervenka, L., & Mitchell, K. 
D. (1999). Concentrations and actions of intraluminal angiotensin II. J Am Soc 
Nephrol, 10 Suppl 11, S189-195.  
Navar, L. G., Lewis, L., Hymel, A., Braam, B., & Mitchell, K. D. (1994). Tubular 
fluid concentrations and kidney contents of angiotensins I and II in anesthetized 
rats. J Am Soc Nephrol, 5(4), 1153-1158.  
Navar, L. G., Prieto, M. C., Satou, R., & Kobori, H. (2011). Intrarenal angiotensin 
II and its contribution to the genesis of chronic hypertension. Curr Opin 
Pharmacol, 11(2), 180-186. doi:10.1016/j.coph.2011.01.009 
Nickenig, G., & Harrison, D. G. (2002). The AT(1)-type angiotensin receptor in 
oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation, 
105(4), 530-536.  
Pages, G. (2007). Sp3-mediated VEGF regulation is dependent on 
phosphorylation by extra-cellular signals regulated kinases (Erk). J Cell Physiol, 
	  	  
	  
	  
	  
	  
138	  	  
	  
	  
	  
213(2), 454-463. doi:10.1002/jcp.21104 
Paravicini, T. M., & Touyz, R. M. (2006). Redox signaling in hypertension. 
Cardiovasc Res, 71(2), 247-258. doi:10.1016/j.cardiores.2006.05.001 
Park, S. W., Noh, H. J., Sung, D. J., Kim, J. G., Kim, J. M., Ryu, S. Y., . . . Cho, 
H. (2015). Hydrogen peroxide induces vasorelaxation by enhancing 4-
aminopyridine-sensitive Kv currents through S-glutathionylation. Pflugers Arch, 
467(2), 285-297. doi:10.1007/s00424-014-1513-3 
Peti-Peterdi, J., Warnock, D. G., & Bell, P. D. (2002). Angiotensin II directly 
stimulates ENaC activity in the cortical collecting duct via AT(1) receptors. J Am 
Soc Nephrol, 13(5), 1131-1135.  
Pfeffer, M. A., Braunwald, E., Moye, L. A., Basta, L., Brown, E. J., Jr., Cuddy, T. 
E., . . . et al. (1992). Effect of captopril on mortality and morbidity in patients with 
left ventricular dysfunction after myocardial infarction. Results of the survival and 
ventricular enlargement trial. The SAVE Investigators. N Engl J Med, 327(10), 
669-677. doi:10.1056/NEJM199209033271001 
Phan, D., Cheng, C. J., Galfione, M., Vakar-Lopez, F., Tunstead, J., Thompson, 
N. E., . . . Lin, S. H. (2004). Identification of Sp2 as a transcriptional repressor of 
	  	  
	  
	  
	  
	  
139	  	  
	  
	  
	  
carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. 
Cancer Res, 64(9), 3072-3078.  
Phillips, M. I., & Schmidt-Ott, K. M. (1999). The Discovery of Renin 100 Years 
Ago. News Physiol Sci, 14, 271-274.  
Pokkunuri, I., Chugh, G., Rizvi, I., & Asghar, M. (2015). Age-related hypertension 
and salt sensitivity are associated with unique cortico-medullary distribution of 
D1R, AT1R, and NADPH-oxidase in FBN rats. Clin Exp Hypertens, 37(1), 1-7. 
doi:10.3109/10641963.2014.977489 
Pokkunuri, I. D., Chugh, G., & Asghar, M. (2013). Human kidney-2 cells harbor 
functional dopamine D1 receptors that require Gialpha for Gq/11alpha signaling. 
Am J Physiol Renal Physiol, 305(4), F560-567. doi:10.1152/ajprenal.00644.2012 
Raijmakers, M. T., Dechend, R., & Poston, L. (2004). Oxidative stress and 
preeclampsia: rationale for antioxidant clinical trials. Hypertension, 44(4), 374-
380. doi:10.1161/01.HYP.0000141085.98320.01 
Redon, J., Oliva, M. R., Tormos, C., Giner, V., Chaves, J., Iradi, A., & Saez, G. T. 
(2003). Antioxidant activities and oxidative stress byproducts in human 
hypertension. Hypertension, 41(5), 1096-1101. 
	  	  
	  
	  
	  
	  
140	  	  
	  
	  
	  
doi:10.1161/01.HYP.0000068370.21009.38 
Rey, F. E., Cifuentes, M. E., Kiarash, A., Quinn, M. T., & Pagano, P. J. (2001). 
Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular 
O(2)(-) and systolic blood pressure in mice. Circ Res, 89(5), 408-414.  
Rodrigo, R., Prat, H., Passalacqua, W., Araya, J., Guichard, C., & Bachler, J. P. 
(2007). Relationship between oxidative stress and essential hypertension. 
Hypertens Res, 30(12), 1159-1167. doi:10.1291/hypres.30.1159 
Ryu, H., Lee, J., Zaman, K., Kubilis, J., Ferrante, R. J., Ross, B. D., . . . Ratan, R. 
R. (2003). Sp1 and Sp3 are oxidative stress-inducible, antideath transcription 
factors in cortical neurons. J Neurosci, 23(9), 3597-3606.  
Safe, S., & Abdelrahim, M. (2005). Sp transcription factor family and its role in 
cancer. Eur J Cancer, 41(16), 2438-2448. doi:10.1016/j.ejca.2005.08.006 
Safe, S., Imanirad, P., Sreevalsan, S., Nair, V., & Jutooru, I. (2014). Transcription 
factor Sp1, also known as specificity protein 1 as a therapeutic target. Expert 
Opin Ther Targets, 18(7), 759-769. doi:10.1517/14728222.2014.914173 
Sapetschnig, A., Koch, F., Rischitor, G., Mennenga, T., & Suske, G. (2004). 
Complexity of translationally controlled transcription factor Sp3 isoform 
	  	  
	  
	  
	  
	  
141	  	  
	  
	  
	  
expression. J Biol Chem, 279(40), 42095-42105. doi:10.1074/jbc.M404989200 
Schafer, G., Cramer, T., Suske, G., Kemmner, W., Wiedenmann, B., & Hocker, 
M. (2003). Oxidative stress regulates vascular endothelial growth factor-A gene 
transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich 
promoter elements. J Biol Chem, 278(10), 8190-8198. 
doi:10.1074/jbc.M211999200 
Schroder, K., Zhang, M., Benkhoff, S., Mieth, A., Pliquett, R., Kosowski, J., 
Brandes, R. P. (2012). Nox4 is a protective reactive oxygen species generating 
vascular NADPH oxidase. Circ Res, 110(9), 1217-1225. 
doi:10.1161/CIRCRESAHA.112.267054 
Sen, C. K., & Packer, L. (1996). Antioxidant and redox regulation of gene 
transcription. FASEB J, 10(7), 709-720.  
Sen, R., & Baltimore, D. (1986a). Inducibility of kappa immunoglobulin enhancer-
binding protein Nf-kappa B by a posttranslational mechanism. Cell, 47(6), 921-
928.  
Sen, R., & Baltimore, D. (1986b). Multiple nuclear factors interact with the 
immunoglobulin enhancer sequences. Cell, 46(5), 705-716.  
	  	  
	  
	  
	  
	  
142	  	  
	  
	  
	  
Shanmugam, S., & Sandberg, K. (1996). Ontogeny of angiotensin II receptors. 
Cell Biol Int, 20(3), 169-176. doi:10.1006/cbir.1996.0021 
Sies, H. (2015). Oxidative stress: a concept in redox biology and medicine. 
Redox Biol, 4, 180-183. doi:10.1016/j.redox.2015.01.002 
Singh, H., Sen, R., Baltimore, D., & Sharp, P. A. (1986). A nuclear factor that 
binds to a conserved sequence motif in transcriptional control elements of 
immunoglobulin genes. Nature, 319(6049), 154-158. doi:10.1038/319154a0 
Stancovski, I., & Baltimore, D. (1997). NF-kappaB activation: the I kappaB kinase 
revealed? Cell, 91(3), 299-302.  
Stegbauer, J., Gurley, S. B., Sparks, M. A., Woznowski, M., Kohan, D. E., Yan, 
M., . . . Coffman, T. M. (2011). AT1 receptors in the collecting duct directly 
modulate the concentration of urine. J Am Soc Nephrol, 22(12), 2237-2246. 
doi:10.1681/ASN.2010101095 
Su, Q., Liu, J. J., Cui, W., Shi, X. L., Guo, J., Li, H. B., . . . Kang, Y. M. (2016). 
Alpha lipoic acid supplementation attenuates reactive oxygen species in 
hypothalamic paraventricular nucleus and sympathoexcitation in high salt-
induced hypertension. Toxicol Lett, 241, 152-158. 
	  	  
	  
	  
	  
	  
143	  	  
	  
	  
	  
doi:10.1016/j.toxlet.2015.10.019 
Su, W., Jackson, S., Tjian, R., & Echols, H. (1991). DNA looping between sites 
for transcriptional activation: self-association of DNA-bound Sp1. Genes Dev, 
5(5), 820-826.  
Sungkaworn, T., Lenbury, Y., & Chatsudthipong, V. (2011). Oxidative stress 
increases angiotensin receptor type I responsiveness by increasing receptor 
degree of aggregation using image correlation spectroscopy. Biochim Biophys 
Acta, 1808(10), 2496-2500. doi:10.1016/j.bbamem.2011.07.007 
Suske, G. (1999). The Sp-family of transcription factors. Gene, 238(2), 291-300.  
Taguchi, H., Ogura, Y., Takanashi, T., Hashizoe, M., & Honda, Y. (1996). In vivo 
quantitation of peroxides in the vitreous humor by fluorophotometry. Invest 
Ophthalmol Vis Sci, 37(7), 1444-1450.  
Takanashi, T., Ogura, Y., Taguchi, H., Hashizoe, M., & Honda, Y. (1997). 
Fluorophotometric quantitation of oxidative stress in the retina in vivo. Invest 
Ophthalmol Vis Sci, 38(13), 2721-2728.  
Talaulikar, V. S., & Manyonda, I. T. (2011). Vitamin C as an antioxidant 
supplement in women's health: a myth in need of urgent burial. Eur J Obstet 
	  	  
	  
	  
	  
	  
144	  	  
	  
	  
	  
Gynecol Reprod Biol, 157(1), 10-13. doi:10.1016/j.ejogrb.2011.03.017 
Tawa, M., Shimosato, T., Iwasaki, H., Imamura, T., & Okamura, T. (2015). 
Different influences of extracellular and intracellular superoxide on relaxation 
through the NO/sGC/cGMP pathway in isolated rat iliac arteries. J Cardiovasc 
Pharmacol, 65(2), 160-167. doi:10.1097/FJC.0000000000000173 
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, 
D. J., Smith, R. D. (1993). Angiotensin II receptors and angiotensin II receptor 
antagonists. Pharmacol Rev, 45(2), 205-251.  
Toledano, M. B., & Leonard, W. J. (1991). Modulation of transcription factor NF-
kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A, 
88(10), 4328-4332.  
Touyz, R. M., & Briones, A. M. (2011). Reactive oxygen species and vascular 
biology: implications in human hypertension. Hypertens Res, 34(1), 5-14. 
doi:10.1038/hr.2010.201 
Ushio-Fukai, M., Alexander, R. W., Akers, M., Lyons, P. R., Lassegue, B., & 
Griendling, K. K. (1999). Angiotensin II receptor coupling to phospholipase D is 
mediated by the betagamma subunits of heterotrimeric G proteins in vascular 
	  	  
	  
	  
	  
	  
145	  	  
	  
	  
	  
smooth muscle cells. Mol Pharmacol, 55(1), 142-149.  
Valdivia, A., Perez-Alvarez, S., Aroca-Aguilar, J. D., Ikuta, I., & Jordan, J. (2009). 
Superoxide dismutases: a physiopharmacological update. J Physiol Biochem, 
65(2), 195-208.  
Vaziri, N. D., Dicus, M., Ho, N. D., Boroujerdi-Rad, L., & Sindhu, R. K. (2003). 
Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase 
in renal insufficiency. Kidney Int, 63(1), 179-185. doi:10.1046/j.1523-
1755.2003.00702.x 
Vaziri, N. D., Lin, C. Y., Farmand, F., & Sindhu, R. K. (2003). Superoxide 
dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced 
hypertension. Kidney Int, 63(1), 186-194. doi:10.1046/j.1523-1755.2003.00711.x 
Vizcaino, C., Mansilla, S., & Portugal, J. (2015). Sp1 transcription factor: A long-
standing target in cancer chemotherapy. Pharmacol Ther, 152, 111-124. 
doi:10.1016/j.pharmthera.2015.05.008 
Wang, D., Chen, Y., Chabrashvili, T., Aslam, S., Borrego Conde, L. J., Umans, J. 
G., & Wilcox, C. S. (2003). Role of oxidative stress in endothelial dysfunction and 
enhanced responses to angiotensin II of afferent arterioles from rabbits infused 
	  	  
	  
	  
	  
	  
146	  	  
	  
	  
	  
with angiotensin II. J Am Soc Nephrol, 14(11), 2783-2789.  
Ward, N. C., Hodgson, J. M., Puddey, I. B., Mori, T. A., Beilin, L. J., & Croft, K. D. 
(2004). Oxidative stress in human hypertension: association with 
antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med, 
36(2), 226-232.  
Wilcox, C. S. (2005). Oxidative stress and nitric oxide deficiency in the kidney: a 
critical link to hypertension? Am J Physiol Regul Integr Comp Physiol, 289(4), 
R913-935. doi:10.1152/ajpregu.00250.2005 
Wilcox, C. S. (2010). Effects of tempol and redox-cycling nitroxides in models of 
oxidative stress. Pharmacol Ther, 126(2), 119-145. 
doi:10.1016/j.pharmthera.2010.01.003 
Wu, F., Park, F., Cowley, A. W., Jr., & Mattson, D. L. (1999). Quantification of 
nitric oxide synthase activity in microdissected segments of the rat kidney. Am J 
Physiol, 276(6 Pt 2), F874-881.  
Yasunari, K., Maeda, K., Nakamura, M., & Yoshikawa, J. (2002). Oxidative stress 
in leukocytes is a possible link between blood pressure, blood glucose, and C-
reacting protein. Hypertension, 39(3), 777-780.  
	  	  
	  
	  
	  
	  
147	  	  
	  
	  
	  
Yu, B., Datta, P. K., & Bagchi, S. (2003). Stability of the Sp3-DNA complex is 
promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters 
containing multiple Sp-sites. Nucleic Acids Res, 31(18), 5368-5376.  
Zhang, Y., & Dufau, M. L. (2003). Repression of the luteinizing hormone receptor 
gene promoter by cross talk among EAR3/COUP-TFI, Sp1/Sp3, and TFIIB. Mol 
Cell Biol, 23(19), 6958-6972.  
Zhao, X., Martin, M. M., & Elton, T. S. (2000). Basal level transcriptional 
regulation of the human angiotensin II type 1 receptor gene. Biochim Biophys 
Acta, 1494(1-2), 181-184.  
Zhao, X., Martin, M. M., & Elton, T. S. (2001). The transcription factors Sp1 and 
Sp3 are required for human angiotensin II type 1 receptor gene expression in 
H295-R cells. Biochim Biophys Acta, 1522(3), 195-206.  
Zinkevich, N. S., & Gutterman, D. D. (2011). ROS-induced ROS release in 
vascular biology: redox-redox signaling. Am J Physiol Heart Circ Physiol, 301(3), 
H647-653. doi:10.1152/ajpheart.01271.2010. 
 
